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Abstract: The marine environment is a rich source of chemically diverse, biologically active natural
products, and serves as an invaluable resource in the ongoing search for novel antimicrobial
compounds. Recent advances in extraction and isolation techniques, and in state-of-the-art
technologies involved in organic synthesis and chemical structure elucidation, have accelerated
the numbers of antimicrobial molecules originating from the ocean moving into clinical trials.
The chemical diversity associated with these marine-derived molecules is immense, varying from
simple linear peptides and fatty acids to complex alkaloids, terpenes and polyketides, etc. Such an
array of structurally distinct molecules performs functionally diverse biological activities against
many pathogenic bacteria and fungi, making marine-derived natural products valuable commodities,
particularly in the current age of antimicrobial resistance. In this review, we have highlighted several
marine-derived natural products (and their synthetic derivatives), which have gained recognition as
effective antimicrobial agents over the past five years (2012–2017). These natural products have been
categorized based on their chemical structures and the structure-activity mediated relationships of
some of these bioactive molecules have been discussed. Finally, we have provided an insight into
how genome mining efforts are likely to expedite the discovery of novel antimicrobial compounds.
Keywords: antimicrobial; marine natural products (MNPs); secondary metabolites; antibacterial;
antifungal; genome mining
1. Introduction
Infectious diseases caused by bacteria, fungi and viruses pose a major threat to public health
despite the tremendous progress in human medicine. A dearth in the availability of effective drugs
and the on-going threats posed by antimicrobial resistant organisms further worsen the situation
particularly in developing countries. Antimicrobial resistance accounts for at least 50,000 deaths
each year in Europe and the United States and it is anticipated that drug resistant infections will
be responsible for the deaths of 10 million people worldwide by 2050 [1,2]. Continuously evolving
antibiotic-resistance of microbial pathogens has raised demands for the development of new and
effective antimicrobial compounds [3]. For generations, humans have turned to nature as a source
of invaluable medicinal products, where terrestrial and marine organisms traditionally provide the
most effective remedies [4,5]. It was only after the discovery of penicillin in 1928 that microbial sources
were explored as sources of new therapeutic molecules. Developments in microbial culture techniques
and diving expeditions in the 1970s have largely directed the drug discovery program towards the
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oceans. Combinatorial chemistry developments in the late 1980s further shifted the emphasis of drug
discovery efforts from nature to the laboratory bench [6]. Although the unique structural features
associated with natural products cannot be matched by any synthetic library they still continue to
inspire researchers in the fields of chemistry, biology, and medicine to develop/synthesize more
drug-like molecules [7]. Natural products, as the name suggests, are products of secondary metabolism
in nature. Traditionally, many natural products were identified as promising candidates for drug
development using bioassay-guided investigations, and chemical structure elucidation techniques [5,8].
However, too often this approach led to the re-isolation of known compounds. Advances in sequencing
and ‘-omics’ technologies are expediting the identification and development of novel molecules. Today,
over 60% of drugs in the market are derived from natural sources [9,10]. Among the 1562 new
chemical entities introduced from the period 1981–2014, 21% are naturally derived, 16% are biological
macromolecules, 10% constitute the nature mimic entities, 9% are botanical drugs, 6% constitute
vaccines and 4% are unaltered natural products [11]. Several small-molecules from natural sources
have been approved as antitumor, antibacterial, and antifungal agents over the period 2011–2014 [11].
In this review, we have discussed the roles played by advances in genomic sequencing and ‘-omics’
technologies in expediting the identification and development of novel, antimicrobial marine natural
products (MNPs) from biosynthetically “talented” microorganisms of marine origin.
2. Marine Natural Products (MNPs)
The ocean covers over 71% of the earth’s surface and constitutes more than 90% of the inhabitable
space on the planet. An estimated 50–80% of all life on earth resides in the ocean and it is home to 32 out
of 33 known animal phyla, 15 of which are exclusively marine [12]. More than 20,000 natural products
have been discovered in the marine environment over the past 50 years [13]. Interest in marine natural
products (MNPs) based drug discovery is evident from the increase in number of isolated MNPs (from
an annual number of approximately 20 in 1984 to an annual number of more than 1000 in 2010) [14,15].
From the continuing progress in the area of MNPs seven approved drugs and 12 agents currently
in clinical trials have been discovered [16]. These molecules are either natural products, tailored
natural products or are molecules inspired from the structure of natural products [17,18]. Marine
organisms largely obtained from shallow-water, tropical ecosystems are the major sources of MNPs.
Macroorganisms such as algae, sponges, corals and other invertebrates, as well as microorganisms
have also contributed significantly towards the discovery of novel MNPs [19]. Marine invertebrates in
particular have proven to be major sources of MNPs in clinical trials [20]. Also, mounting evidence
suggests that many of the compounds originally associated with the biomass of macroorganisms such
as sponges [21], tunicates [22], molluscs [23] amongst others, are not produced by the organism itself
but are synthesized by symbiotic or associated microorganisms, or derive from a diet of prokaryotic
microorganisms [24]. Unlike the terrestrial environment, where plants are comparatively richer in
secondary metabolites, marine invertebrates and bacteria have yielded substantially more bioactive
natural products than marine plants [25].
The total number of approved drugs from the marine environment steadily increased from
four in 2010 to seven in 2014 [26,27]. The first U.S. Food and Drug Administration (FDA) approved
marine-derived drug cytarabine (Cytosar-U®), isolated from the Caribbean sponge Cryptotheca crypta,
reached the market in 1969 for use as an anticancer drug. Since then, six more marine natural products
have moved through clinical trials and have been approved as drugs (one of which is only registered
in the European Union), including the analgesic cone snail-derived peptide ziconotide (Prialt®),
and the anticancer sponge-derived macrolide, eribulin mesylate (Halaven®), as well as four other
products with anticancer, antiviral and antihypertriglyceridemia activities [27]. Of the 23 most recently
identified marine-derived compounds, 21 are in several different stages of the clinical pipeline for
use as anticancer agents, while two of them are being assessed for treatment of chronic pain and
neurological disorders like schizophrenia and Alzheimer’s disease [7]. In addition, a number of other
compounds boasting antibacterial, antidiabetic, antifungal, antiinflammatory and antiviral properties,
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as well as compounds potentially affecting the nervous system, are currently being investigated for
use in clinical settings and thus form part of the preclinical pipeline [27–29].
3. Chemical Entities in the Preclinical Antimicrobial Pipeline
Over the last 5 years, preclinical pharmacology has been undertaken on 262 marine compounds
that are presently at various stages of clinical investigations [26]. Herein, we discuss the structural
features of some of these molecules (Figure 1) which are currently under investigation for their potential
as antimicrobial agents. Where noted in the text, bold numerical values correspond to their associated
structures in corresponding figures.
Mar. Drugs 2017, 15, 272 3 of 40 
 
prop rties, as well a  c mpounds po e tially affecting th  nervous sys em, are currently being 
investigated for use in clinical ettings nd thus form part of the preclinical pipeline [27–29]. 
. ic l titi s i  t  r cli ic l ti icr i l i li  
r t  l st  rs, r cli ic l r c l  s  rt    ri  c s 
t t r  r s tl  t ri s st s f cli ic l i sti ti s [ ]. r i ,  isc ss t  str ct r l 
f t r s of some of these molecules (Figure 1) which ar  currently under investigation for their 
potential as antimicrobial agents. Where not d in the text, bold num rical values correspond to th ir 
asso iat d structures i  corresponding figures. 
 
Figure 1. Marine natural products in antimicrobial preclinical studies. 
Chrysophaentin A (1), a macrocyclic natural product (comprising two polyhalogenated, 
polyoxygenated ω,ω′-diarylbutene units connected by two ether bonds), was isolated from the 
chrysophyte alga Chrysophaeum taylori. This compound inhibits the growth of clinically relevant 
Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA; MIC50 1.5 ± 0.7 
μg/mL), multiple drug resistant S. aureus (MIC50 1.3 ± 0.4 μg/mL), and Vancomycin-Resistant Enterococcus 
faecium (VREF; MIC50 2.9 ± 0.8 μg/mL). Chrysophaentin A inhibits the GTPase activity of the bacterial 
cytoskeletal protein FtsZ (IC50 value 6.7 μg/mL), and GTP-induced formation of FtsZ protofilaments 
[30]. Interestingly, this compound was found to be relatively more active among its congeners, 
Chrysophaentins B–G (2–7). Analysis of bioactivity of these molecules provided insights into the 
pharmacophoric features of Chrysophaentins relevant to antimicrobial activity. Phenolic groups in 
compound 1 were determined to be crucial for activity as a hexaacetate derivative of 1 was found to 
be inactive at a concentration 25 μg/disk. An approximate 12-fold decrease in the MIC50 value of 
chrysophaentin D (4) compared to compound 1 was observed on replacement of chlorine with 
bromine on rings A and C. The significance of the macrocyclic structure was established following 
higher MIC50 values of Chrysophaentin E (5) being observed towards S. aureus and MRSA compared 
Figure 1. Marine natural products in antimicrobial preclinical studies.
Chrysophaentin A (1), a macrocyclic natural product (comprising two polyhalogenated,
polyoxygenated ω,ω′-diarylbutene units connected by two ether bonds), was isolated from
the chrysophyte alga Chrysophaeum taylori. This compound inhibits the growth of clinically
relevant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA;
MIC50 1.5 ± 0.7 µg/mL), multiple drug resistant S. aureus (MIC50 1.3 ± 0.4 µg/mL), and
Vancomycin-Resistant Enterococcus faecium (VREF; MIC50 2.9 ± 0.8 µg/mL). Chrysophaentin A inhibits
the GTPase activity of the bacterial cytoskeletal protein FtsZ (IC50 value 6.7 µg/mL), and GTP-induced
formation of FtsZ protofilaments [30]. Interestingly, this compound was found to be relatively more
active among its congeners, Chrysophaentins B–G (2–7). Analysis of bioactivity of these molecules
provided insights into the pharmacophoric features of Chrysophaentins relevant to antimicrobial
activity. Phenolic groups in compound 1 were determined to be crucial for activity as a hexaacetate
derivative of 1 was found to be inactive at a concentration 25 µg/disk. An approximate 12-fold decrease
in the MIC50 value of chrysophaentin D (4) compared to compound 1 was observed on replacement of
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chlorine with bromine on rings A and C. The significance of the macrocyclic structure was established
following higher MIC50 values of Chrysophaentin E (5) being observed towards S. aureus and MRSA
compared to MIC50 values observed for the chlorinated cyclic bisdiarylbutene ethers 1 and 6. However,
compound 5 was also found to be inactive toward E. faecium and VREF at concentrations as high
as 25 µg/mL. In the case of the symmetrically linked dimers 6 and 7, replacing a chlorine atom on
ring C with bromine confers compound 6 with at least three times better activity than compound 7.
Among the tetrachlorinated macrocyles 1 and 6, compound 1 was found to be 3–5 times more potent
than compound 6, indicating that the position of the ether linkage relative to the 2-butene unit affects
activity. In fact, ortho-linked chrysophaentin A has been found to be more potent than the para-linked
chrysophaentin F [31].
A small cyclopropane-containing fatty acid, lyngbyoic acid (8), was found to be a major metabolite
of the marine cyanobacterium, Lyngbya cf. majuscula, isolated in Florida [32]. This molecule exerts
antimicrobial action by disrupting quorum sensing in Pseudomonas aeruginosa. At a concentration
of 100 µM, it inhibits the N-acyl homoserine lactone (HSL) receptor proteins in the organism
(LasR in particular), reducing the expression of important virulence factors in the wild-type
strain. The molecules inhibit the response of LasR-based QS reporter plasmids to 3-oxo-C 12-HSL.
The AHL-binding site of LasR was not essential to this effect, but competition experiments indicated
that compound 8 is likely to have a dual mechanism of action acting both through the AHL-binding
site and independently of it. Comparison of compound 8 with related compounds (dodecanoic acid, 9;
malyngolide, 10; and lyngbic acid, 11; methyl ester of dodecanoic acid, 12 and butyric acid, 13) revealed
a structure-activity relationship. While compounds 9, 10 and 11 had a similar potency in pSB1075
compared to 8, either esterification (12) or shortening of the alkyl chain (13) reduced activity [32].
Two sulfated sterols, geodisterol-3-O-sulfite (14) and 29-demethylgeodisterol-3-O-sulfite (15),
were isolated from the marine sponge Topsentia sp. These sulfated sterols demonstrated reverse efflux
pump-mediated fluconazole resistance. They enhanced the activity of fluconazole in a Saccharomyces
cerevisiae strain overexpressing the Candida albicans efflux pump MDR1, and in a fluconazole-resistant
C. albicans clinical isolate known to overexpress MDR1. No activity for non-sulfated sterol in
fluconazole-resistance reversal assay had been observed highlighting the relevance of sulfate group for
MDR1 inhibition and synergy with fluconazole. Investigation of the geodisterols had provided insight
into the clinical utility of combining efflux pump inhibitors with current antifungals to combat the
resistance associated with opportunistic fungal infections caused by C. albicans [33].
In the following sections, we present a systematic overview of the marine natural products which
have gained the attention of chemists and biologists over the last five years (2012–2017) as potential
antimicrobial agents. The molecules are categorized according to their chemical class based on their
associated structural units. Pharmacophoric features responsible for antimicrobial activity are also
discussed. Table 1 lists MNPs and describes their antimicrobial potential in terms of MICs and zone
of inhibition.
Table 1. Chemical classification of antimicrobial marine natural products (MNPs). MRSA:
methicillin-resistant Staphylococcus aureus; MRSE: methicillin-resistant Staphylococcus epidermidis MSSA:
methicillin-sensitive Staphylococcus aureus; MTCC: microbial type culture collection.
Compound Source Activity Against Pathogen
Alkaloids
Pyranonigrin A (16) Penicillium brocae MA-231
S. aureus (MIC 0.5 µg/mL)
V. harveyi (MIC 0.5 µg/mL)
V. parahaemolyticus (MIC 0.5 µg/mL)
A. brassicae (MIC 0.5 µg/mL)
C. gloeosprioide (MIC 0.5 µg/mL)
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Table 1. Cont.
Compound Source Activity Against Pathogen
Pyranonigrin F (17) P. brocae MA-231
S. aureus (MIC 0.5 µg/mL)
V. harveyi (MIC 0.5 µg/mL)
Vibrio parahaemolyticus (MIC 0.5 µg/mL)
Alternaria brassicae (MIC 0.5 µg/mL)
C. gloeosprioide (MIC 0.5 µg/mL)
Rubrumazine B (18) E. cristatum EN-220 Magnaporthe grisea (MIC 64 µg/mL)
Echinulin (19) E. cristatum EN-220 S. aureus (MIC 256 µg/mL)
Dehydroechinulin (20) E.cristatum EN-220 S. aureus (MIC 256 µg/mL)
Variecolorin H (21) E. cristatum EN-220 S. aureus (MIC 256 µg/mL)
Cristatumin A (22) E.cristatum
E. coli (MIC 64 µg/mL)
S. aureus (MIC 8 µg/mL)
Cristatumin D (23) E. cristatum S. aureus (Zone of inhibition 8 mm at 100 µg/disk)
Tardioxopiperazine A (24) E. cristatum
E. coli (MIC 64 µg/mL)
S. aureus (MIC 8 µg/mL)
Hemimycalin A (27) Hemimycale arabica E. coli (Inhibition zone 18 mm at 100 µg/disk)
C. albicans (Inhibition zone 22 mm at 100 µg/disk)
Hemimycalin B (28) H. arabica
E. coli (Inhibition zone 10 mm at 100 µg/disk)
C. albicans (Inhibition zone 14 mm at 100 µg/disk)
(Z)-5-(4-
hydroxybenzylidene)imidazolidine-
2,4-dione (29)
H. arabica
E. coli (Inhibition zone 20 mm at 100 µg/disk)
C. albicans (Inhibition zone 20 mm at 100 µg/disk)
Peniciadametizine A (30) Penicillium adametzioides A. brassicae (MIC 4 µg/mL)
Peniciadametizine B (31) P. adametzioides A. brassicae (MIC 32 µg/mL)
Penicibrocazine B (33) P. brocae
S. aureus (MIC 32 µg/mL)
G.graminis (MIC 0.25 µg/mL)
Penicibrocazine C (34) P. brocae
S. aureus (MIC 0.25 µg/mL)
M. luteus (MIC 0.25 µg/mL)
Penicibrocazine D (35) P. brocae
S. aureus (MIC 8 µg/mL)
G.graminis (MIC 8 µg/mL)
Penicibrocazine E (36) P. brocae G. graminis (MIC 0.25 µg/mL)
Crambescidin 800 (37) Clathria cervicornis
A. baumannii (MIC 2 µg/mL)
K. pneumonia (MIC 1 µg/mL)
P. aeruginosa. (MIC 1 µg/mL)
Xinghaiamine A (38) Streptomyces xinghaiensis
S. aureus (MIC 0.69 µM)
B. subtilis (MIC 0.35 µM)
E. coli (MIC 0.17 µM)
A. baumanii (MIC 2.76 µM)
P. aeruginosa (MIC 11 µM)
MRSA 5301 (MIC 5.52 µM)
MRSA 5438 (MIC 2.76 µM)
MRSA 5885 (MIC 5.52 µM)
Hyrtioerectine D (39) Hyrtios sp.
C. albicans (Zone of inhibition 17 mm at 100 µg/disk)
S. aureus (Zone of inhibition 20 mm at 100 µg/disk)
P. aeruginosa (Zone of inhibition 9 mm at 100 µg/disk)
Hyrtioerectine E (40) Hyrtios sp.
C. albicans (Zone of inhibition 19 mm at 100 µg/disk)
S. aureus (Zone of inhibition 10 mm at 100 µg/disk)
P. aeruginosa (Zone of inhibition 9 mm at 100 µg/disk)
Hyrtioerectine F (41) Hyrtios sp.
C. albicans (Zone of inhibition 14 mm at 100 µg/disk)
S. aureus (Zone of inhibition 16 mm at 100 µg/disk)
P. aeruginosa (Zone of inhibition 9 mm at 100 µg/disk)
Ageloxime B (42) Agelas mauritiana C. neoformans (MIC 5 µg/mL)
S. aureus (MIC 7 µg/mL)
Ageloxime D (43) A. mauritiana C. neoformans (MIC 6 µg/mL)
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Compound Source Activity Against Pathogen
Zamamidine D (44) Amphimedon sp.
E. coli (MIC 32 µg/mL)
S. aureus (MIC 8 µg/mL)
B. subtilis (MIC 8 µg/mL)
M. luteus (MIC 8 µg/mL)
A. niger (MIC 16 µg/mL)
T. mentagrophytes (MIC 8 µg/mL)
C. albicans (MIC 16 µg/mL)
C. neoformans (MIC 2 µg/mL)
Adametizine A (45) P. adametzioides AS-53
S.aureus (MIC 8 µg/mL)
A. hydrophilia (MIC 8 µg/mL)
V. harveyi (MIC 32 µg/mL)
V. parahaemolyticus (MIC 8 µg/mL)
G. graminis (MIC 16 µg/mL)
Adametizine B (46) P.adametzioides AS-53 S. aureus (MIC 64 µg/mL)
Iso-Agelasidine B (47) A. nakamurai C. albicans (MIC 2.34 µg/mL)
(−)-Agelasidine C (48) A. nakamurai C. albicans (MIC 2.34 µg/mL)
Iso-agelasine C (49) A. nakamurai
S. aureus (MIC 75 µg/mL)
E. coli (MIC 150 µg/mL)
P. vulgaris (MIC 19 µg/mL)
C. albicans (MIC 5 µg/mL)
Agelasine B (50) A. nakamurai
P. vulgaris (MIC 19 µg/mL)
C. albicans (MIC 2 µg/mL)
Agelasine J (51) A. nakamurai
S. aureus (MIC 75 µg/mL)
E. coli (MIC 75 µg/mL)
P. vulgaris (MIC 9 µg/mL)
C. albicans (MIC 0.6 µg/mL)
Nemoechine G (52) A. nakamurai
S. aureus (MIC 150 µg/mL)
E. coli (MIC 75 µg/mL)
P. vulgaris (MIC 9 µg/mL)
C. albicans (MIC 0.6 µg/mL)
Brevianamide F (53) Penicillium vinaceum
C. albicans (Zone of inhibition 25 mm at 100 µg/disk)
S. aureus (Zone of inhibition 19 mm at 100 µg/disk)
N-(2-hydroxyphenyl)-
2-phenazinamine (54) Nocardia dassonvillei C. albicans (MIC of 64 µg/mL)
Terpenoids
Puupehenol (55) Dactylospongia sp. S. aureus (Zone of inhibition 4 mm at 10 µg/disk)
B. cereus (Zone of inhibition 4 mm at 10 µg/disk)
Puupehenone (56) Dactylospongia sp. S. aureus (Zone of inhibition 3 mm at 10 µg/disk)
B. cereus (Zone of inhibition 3 mm at 10 µg/disk)
Penicibilaene A (57) Penicillium bilaiae C. gloeosporioides (MIC 1 µg/mL)
Penicibilaene B (58) P. bilaiae C. gloeosporioides (MIC 0.1 µg/mL)
Aspergillusene A (59) Aspergillus sydowii K. pneumonia (MIC 21 µM)
A. hydrophila (MIC 4.3 µM)
(Z)-5-(Hydroxymenthyl)-2-
(6′)-methylhept-2′-en-2′-yl)-phenol
(60)
A. sydowii K. pneumonia (MIC 11 µM)
Sydonic acid (61) A. sydowii E. faecalis (MIC 19 µM)
12-hydroxy isolaurene (62) Laurencia obtuse
B. subtilis (MIC 46 µg/mL)
S. aureus (MIC 52 µg/mL)
8,11-dihydro-12-hydroxy
isolaurene (63) L. obtuse
C. albicans (MIC 120 µg/mL)
A. fumigatus (MIC 200 µg/mL)
B. subtilis (MIC 39 µg/mL)
S. aureus (MIC 31 µg/mL)
Isolauraldehyde (64) L. obtuse
C. albicans (MIC 70 µg/mL)
A. fumigatus (MIC 100 µg/mL)
B. subtilis (MIC 35 µg/mL)
S. aureus (MIC 27 µg/mL)
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Table 1. Cont.
Compound Source Activity Against Pathogen
Napyradiomycin 1 (65) Streptomyces strain MRSA (MIC 16 µg/mL)
Napyradiomycin 2 (66) Streptomyces strain MRSA (MIC 64 µg/mL)
Napyradiomycin B2 (67) Streptomyces strain MRSA (MIC 32–64 µg/mL)
Napyradiomycin B3 (68) Streptomyces strain MRSA (MIC 2 µg/mL)
Napyradiomycin B4 (69) Streptomyces strain MRSA (MIC 32 µg/mL)
Dixiamycins A (70) Streptomyces sp.
E. coli (MIC 8 µg/mL)
S. aureus (MIC 8 µg/mL)
B. subtilis (MIC 16 µg/mL)
B. thuringensis (MIC 4 µg/mL)
Dixiamycins B (71) Streptomyces sp.
E. coli (MIC 8 µg/mL)
S. aureus (MIC 16 µg/mL)
B. subtilis (MIC 16 µg/mL)
B. thuringensis (MIC 8 µg/mL)
Oxiamycin (72) Streptomyces sp. E. coli (MIC 64 µg/mL)
S. aureus (MIC 128 µg/mL)
Chloroxiamycin (73) Streptomyces sp.
E. coli (MIC 64 µg/mL)
S. aureus (MIC 64 µg/mL)
B. thuringensis (MIC 64 µg/mL)
Xiamycin A (74) Streptomyces sp. E. coli (MIC 64 µg/mL)
S. aureus (MIC 64 µg/mL)
Sarcotrocheliol acetate (75) Sarcophyton trocheliophorum
S. aureus (MIC 1.7 µM)
MRSA (MIC 1.7 µM)
Acinetobacter pp. (MIC 4.3 µM)
Sarcotrocheliol (76) S. trocheliophorum
S. aureus (MIC 1.5 µM)
MRSA (MIC 3.0 µM)
Acinetobacter sp. (MIC 3.0 µM)
Cembrene-C (77) S. trocheliophorum C. albicans (MIC 0.7 µM)A. flavus (MIC 0.7 µM)
Sarcophine (78) S. trocheliophorum
S. aureus (MIC 9.4 µM)
MRSA (MIC 9.4 µM)
Acinetobacter sp. (MIC 9.4 µM)
Palustrol (79) S. trocheliophorum
S. aureus (MIC 6.6 µM)
MRSA (MIC 6.6 µM)
Acinetobacter sp. (MIC 11.1 µM)
epi-Ilimaquinone (80) Hippospongia sp.
MRSA (MIC 63 µg/mL)
S. aureus (MIC 31 µg/mL)
Vancomycin resistant E. faecium (MIC 16 µg/mL)
Amphotericin-resistant C. albicans (MIC 125 µg/mL)
Penicillosides A (81) Penicillium sp. C. albicans (inhibition zone 23 mm at 100 µg/disk)
Penicillosides B (82) Penicillium sp. S. aureus (inhibition zone 19 mm at 100 µg/disk)E. coli (inhibition zone 20 mm at 100 µg/disk)
Ieodoglucomide A (83) Bacillus licheniformis
S. aureus (MIC 8 µg/mL)
B. subtilis (MIC 16 µg/mL)
B. cereus (MIC 16 µg/mL)
S. typi (MIC 16 µg/mL)
E. coli (MIC 8 µg/mL)
P. aeruginosa (MIC 8 µg/mL)
A. niger (MIC 32 µg/mL)
C. albicans (MIC 32 µg/mL)
Ieodoglucomide B (84) B. licheniformis
S. aureus (MIC 8 µg/mL)
B. subtilis (MIC 16µg/mL)
B. cereus (MIC 8 µg/mL)
S. typi (MIC 16 µg/mL)
E. coli (MIC 16µg/mL)
P. aeruginosa (MIC 8 µg/mL)
A. niger (MIC 32 µg/mL)
C. albicans (MIC 16 µg/mL)
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Table 1. Cont.
Compound Source Activity Against Pathogen
Iedoglucomide C (85) Bacillus licheniformis
S. aureus (MIC 0.03 µM)
B. subtilis (MIC 0.03 µM)
B. cereus (MIC 0.01 µM)
S. typi (MIC 0.01 µM)
E. coli (MIC 0.01 µM)
P. aeruginosa (MIC 0.01 µM)
A. niger (MIC 0.05 µM)
R. solani (MIC 0.05 µM)
C. acutatum (MIC 0.03 µM)
B. cenerea (MIC 0.03 µM)
C. albicans (MIC 0.03 µM)
Iedoglycoloipd (86) B. licheniformis
S. aureus (MIC 0.03 µM)
B. subtilis (MIC 0.05 µM)
B. cereus (MIC 0.03 µM)
S. typi (MIC 0.05 µM)
E. coli (MIC 0.03 µM)
P. aeruginosa (MIC 0.03 µM)
A. niger (MIC 0.03 µM)
R. solani (MIC 0.05 µM)
C. acutatum (MIC 0.03 µM)
B. cenerea (MIC 0.03 µM)
C. albicans (MIC 0.05 µM)
Gageotetrin A (87) Bacillus subtilis
C. acutatum (MIC 0.03 µM)
B. cinera. (MIC 0.03 µM)
S. aureus (MIC 0.03 µM)
B. subtilis (MIC 0.03 µM)
Gageotetrin B (88) B. subtilis
C. acutatum (MIC 0.01 µM)
B. cinera. (MIC 0.01 µM)
S. aureus (MIC 0.04 µM)
B. subtilis (MIC 0.02 µM)
Gageotetrin C (89) B. subtilis
C. acutatum (MIC 0.02 µM)
B. cinera (MIC 0.01 µM)
S. aureus (MIC 0.04 µM)
B. subtilis (MIC 0.04 µM)
Lauramide diethanolamine (90) Streptomyces sp.
B. subtilis (MIC 0.055 µg/mL)
E. coli (MIC 0.055 µg/mL)
P. aeruginosa (MIC 0.011 µg/mL)
S. aureus (MIC 0.011 µg/mL)
S. cerevisiae (MIC 0.022 µg/mL)
Linieodolide A (91) Bacillus sp.
B. subtilis (MIC 8 µg/mL)
E. coli (MIC 8 µg/mL)
S. cerevisiae (MIC 32 µg/mL)
Linieodolide B (92) Bacillus sp.
B. subtilis (MIC 64 µg/mL)
E. coli (MIC 64 µg/mL)
S. cerevisiae (MIC 128 µg/mL)
Dysiroid A (93) Dysidea sp.
S. aureus ATCC 29213 (MIC 4 µg/mL)
S. aureus ATCC 43300(MIC 8 µg/mL)
E. faecalis ATCC 29212(MIC 4 µg/mL)
B. licheniformis ATCC 10716 (MIC 16 µg/mL)
Dysiroid B (94) Dysidea sp.
S. aureus ATCC 29213 (MIC 4 µg/mL)
S. aureus ATCC 43300(MIC 4 µg/mL)
E. faecalis ATCC 29212(MIC 4 µg/mL)
B. licheniformis ATCC 10716 (MIC 8 µg/mL)
Halistanol sulfate A (95) Petromica ciocalyptoides S. mutans clinical isolate (MIC 15 µg/mL)S. mutans UA159 (MIC 15 µg/mL)
Peptides
Rodriguesines A and B (96 and
96a)
Didemnum sp. S. mutans clinical isolate (MIC 31 µg/mL)
S. mutans UA159 (MIC 62 µg/mL)
Cyclo-(L-valyl-D-proline) (97) Rheinheimera japonica
S. aureus (Zone of inhibition 17 mm at 0.5 mg/mL)
V. parahaemolyticus (MIC 0.05 µg/mL)
V. vulnificus (MIC 5 µg/mL)
M. luteus (MIC 5 µg/mL)
Mar. Drugs 2017, 15, 272 9 of 42
Table 1. Cont.
Compound Source Activity Against Pathogen
Cyclo-(L-phenylalanyl-D-proline
(98) R. japonica S. aureus (Zone of inhibition 15 mm at 0.5 mg/mL)
Cyclo-(S-Pro-R-Leu) (99) Haliclona oculata
V. parahaemolyticus (MIC 0.5 µg/mL)
V. vulnificus (MIC 5 µg/mL)
B. cereus (MIC 0.05 µg/mL)
Isaridin G (100) Beauveria felina EN-135 E. coli (MIC 64 µg/mL)
Desmethylisaridin G (101) B. felina EN-135 E. coli (MIC 64 µg/mL)
Desmethylisaridin C1(102) B. felina EN-135 E. coli (MIC 8 µg/mL)
Isaridin E (103) B. felina EN-135 E. coli (MIC 16 µg/mL)
Desotamide (104) Streptomyces scopuliridisSCSIO ZJ46
S. pnuemoniae (MIC 13 µg/mL)
S. aureus (MIC 16 µg/mL)
MRSE (MIC 32 µg/mL)
Desotamide B (105) S. scopuliridis SCSIO ZJ46
S. pnuemoniae (MIC 13 µg/mL)
S. aureus (MIC 16 µg/mL)
MRSE (MIC 32 µg/mL)
Halogenated Compounds
2-(2′,4′-dibromophenoxy)-
3,5-dibromophenol (106)
Dysidea granulosa
MSSA (MIC 1 mg/L)
L. monocytogenes (MIC 2 mg/L)
B. cereus (MIC 0.1 mg/L)
C. diffiile (MIC 4 mg/L)
MRSA (MIC 0.1 mg/L)
Salmonella sp. (MIC 1 mg/L)
E. coli O157:H7 (MIC 8 mg/L)
Pseudomonas (MIC 4 mg/L)
K. pneumoniae (MIC 0.1 mg/L)
N. gonorrhoeae (MIC 2 mg/L)
A. baumannii (MIC 16 mg/L)
C. jejuni (MIC 5 mg/L)
2-(2′,4′-dibromophenoxy)-
3,4,5-tribromophenol (107)
Dysidea granulosa
L. monocytogenes (MIC 0.1 mg/L)
C. diffiile (MIC 10 mg/L)
MRSA (MIC 0.1 mg/L)
Salmonella sp. (MIC 10 mg/L)
C. jejuni (MIC 5 mg/L)
2-(2′,4′-dibromophenoxy)-
4,6-dibromophenol (108)
Dysidea sp.
L. monocytogenes (MIC 1 mg/L)
B. cereus (MIC 5 mg/L)
S. pneumoniae (MIC 5 mg/L)
C. diffiile (MIC 10 mg/L)
MRSA (MIC 1 mg/L)
Salmonella sp. (MIC 10 mg/L)
E. coli O157:H7 (MIC 10 mg/L)
K. pneumoniae (MIC 5 mg/L)
C. jejuni (MIC 5 mg/L)
Aplysamine 8 (109) Pseudoceratina purpurea E. coli (MIC 125 µg/mL)
S. aureus (MIC 31 µg/mL)
Sphaerodactylomelol (113) Sphaerococcus coronopifolius S. aureus (MIC 96 µM)
Bromosphaerol (114) Sphaerococcus coronopifolius S. aureus (MIC 22 µM)
12R-hydroxybromosphaerol (115) Sphaerococcus coronopifolius S. aureus (MIC 6 µM)
6-bromoindolyl-3-acetic acid (116) Pseudoalteromonas flavipulchra V. anguillarum (MIC 0.25 mg/mL)
Nagelamide X (117) Agelas sp.
S. aureus (MIC 8 µg/mL)
M. luteus (MIC 8 µg/mL)
A. niger (IC50 32 µg/mL)
T. mentagrophytes (IC50 16 µg/mL)
C. albicans (IC50 2 µg/mL)
Nagelamide Y (118) Agelas sp. C. albicans (IC50 2 µg/mL)
Nagelamide Z (119) Agelas sp.
S. aureus (MIC 16 µg/mL)
M. luteus (MIC 8 µg/mL)
A. niger (IC50 4 µg/mL)
T. mentagrophytes (IC50 4 µg/mL)
C. albicans (IC50 0.25 µg/mL)
C. neoformans (IC50 2 µg/mL)
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Compound Source Activity Against Pathogen
Ianthelliformisamine A (120) Suberea ianthelliformis P. aeruginosa (IC50 7 µM)
Ianthelliformisamine C (122) Suberea ianthelliformis P. aeruginosa (IC50 9 µM)S. aureus (IC50 4µM)
Polyketides
N-acetyl-N-demethylmayamycin
(123) Streptomyces sp. 182SMLY MRSA (MIC 20 µM)
Lindgomycin (124) Lindgomycetaceae strain
B. subtilis (MIC 2.2 µM)
X. campestris (MIC 17.8 µM)
S. epidermidis (MIC 4.6 µM)
S. aureus (MIC 2.7 µM)
S. aureus (MRSA) (MIC 5.1 µM)
C. albicans (MIC 5.7 µM)
S. tritici (MIC 5.1 µM)
P. acnes (MIC 4.7 µM)
Ascosetin (125) Lindgomycetaceae strain
B. subtilis (MIC 3.4 µM)
X. campestris (MIC 14.8 µM)
S. epidermidis (MIC 6.3 µM)
S. aureus (MIC 2.9 µM)
S. aureus (MRSA) (MIC 3.2 µM)
C. albicans (MIC 8 µM)
S. tritici (MIC 10 µM)
P. acnes (MIC 2.8 µM)
Manadodioxan E (127) Plakortis bergquistae E. coli (Zone of inhibition 16 mm at 10 µg/disk)B. cereus (Zone of inhibition 9 mm at 10 µg/disk)
2-(7-(2-Ethylbutyl)-2,3,4,4a,6,7-
hexahydro-2-oxopyrano-[3,2b]-
pyran-3-yl)-ethyl benzoate (128)
B. subtilis MTCC 10407
V. parahemolyticus (Zone of inhibition 11 mm at 10 µg/disk)
V. vulnificus (Zone of inhibition 13 mm at 10 µg/disk)
A. hydrophilla (Zone of inhibition 18 mm at 10 µg/disk)
2-((4Z)-2-ethyl-octahydro-6-oxo-3-
((E)-pent-3-enylidene)-pyrano-[3,2b]-
pyran-7-yl)-ethyl benzoate (129)
B. subtilis MTCC 10407
V. parahemolyticus (Zone of inhibition 11 mm at 10
µg/disk/mL)
V. vulnificus (Zone of inhibition 14 mm at 10 µg/disk)
A. hydrophilla (Zone of inhibition 15 mm at 10 µg/disk)
3-(methoxycarbonyl)-4-(5-
(2-ethylbutyl)-5,6-dihydro-3-methyl-
2H-pyran-2-yl)-butyl benzoate
(130)
Sargassum myriocystum
V. parahemolyticus (Zone of inhibition 7 mm at 10 µg/disk)
V. vulnificus (Zone of inhibition 7 mm at 10 µg/disk)
A. hydrophilla (Zone of inhibition 8 mm at 10 µg/disk)
2-(8-butyl-3-ethyl-3,4,4a,5,6,
8ahexahydro-2H-chromen-6-yl)-ethyl
benzoate (131)
Sargassum myriocystum
V. parahemolyticus (Zone of inhibition 9 mm at 10 µg/disk)
V. vulnificus (Zone of inhibition 8 mm at 10 µg/disk
A. hydrophilla (Zone of inhibition 7 mm at 10 µg/disk)
Fradimycin A (132) Streptomyces fradiae S. aureus (MIC 6 µg/mL)
Fradimycin B (133) Streptomyces fradiae S. aureus (MIC 2 µg/mL)
Glycosylated Macrolactin A1 (134) Streptomyces sp.
B. subtilis (MIC 0.027 µg/mL)
E. coli (MIC 0.022 µg/mL)
P. aeruginosa (MIC 0.055 µg/mL)
S. aureus (MIC 0.055 µg/mL)
S. cerevisiae (MIC 0.022 µg/mL)
Glycosylated Macrolactin B1 (135) Streptomyces sp.
B. subtilis (MIC 0.055 µg/mL)
E. coli (MIC 0.022 µg/mL)
P. aeruginosa (MIC 0.055 µg/mL)
S. aureus (MIC 0.055 µg/mL)
S. cerevisiae (MIC 0.022 µg/mL)
Macrolactin X (136) Bacillus sp.
B. subtilis (MIC 16 µg/mL)
E. coli (MIC 16 µg/mL)
S. cerevisiae (MIC 64 µg/mL)
Macrolactin Y (137) Bacillus sp.
B. subtilis (MIC 16 µg/mL)
E. coli (MIC 32 µg/mL)
S. cerevisiae (MIC 64 µg/mL)
Macrolactin Z (138) Bacillus sp.
B. subtilis (MIC 16 µg/mL)
E. coli (MIC 32 µg/mL)
S. cerevisiae (MIC 64 µg/mL)
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Macrolactinic acid (139) Bacillus sp.
B. subtilis (MIC 64 µg/mL)
E. coli (MIC 32 µg/mL)
S. cerevisiae (MIC 128 µg/mL)
Heronamycin A (140) Streptomyces sp. B. subtilis ATCC 6051 (MIC 18 µM)
B. subtilis ATCC (MIC 14 µM)
Herbimycin A (141) Streptomyces sp.
B. subtilis ATCC 6051 (MIC 5 µM)
B. subtilis ATCC (MIC 5 µM)
C. albicans ATCC 90028 (MIC 7 µM)
3-(Octahydro-9-isopropyl-2H-
benzo[h]chromen-4-yl)-2-
methylpropyl benzoate (142)
Bacillus amyloliquefaciens
V. parahemolyticus (Zone of inhibition 14 mm at 25 µg/disk)
V. vulnificus (Zone of inhibition 16 mm at 25 µg/disk)
A. hydrophilla (Zone of inhibition 18 mm at 25 µg/disk)
Methyl
8-(2-(benzoyloxy)ethyl)-hexahydro-
4-((E)-pent-2-enyl)-2H-chromene-
6-carboxylate (143)
Bacillus amyloliquefaciens
V. parahemolyticus (Zone of inhibition 12 mm at 25 µg/disk)
V. vulnificus (Zone of inhibition 14 mm at 25 µg/disk)
A. hydrophilla (Zone of inhibition 16 mm at 25 µg/disk)
3-O-(α-D-ribofuranosyl)questin
(144) Eurotium cristatum E. coli (MIC 32 µg/mL)
Eurorubrin (145) Eurotium cristatum E. coli (MIC 64 µg/mL)
Isocoumarins
Penicisimpins A (146) Penicillium simplicissimum
MA-332
A. hydrophilia (MIC > 64µg/mL)
E. coli (MIC 4 µg/mL)
M. luteus (MIC 8 µg/mL)
P. aeruginosa (MIC 4 µg/mL)
V. alginolyticus (MIC 8µg/mL)
V. harveyi (MIC 4 µg/mL)
V. parahaemolyticus (MIC 4 µg/mL)
C. gloeosprioides (MIC 4 µg/mL)
Penicisimpins B (147) Penicillium simplicissimum
MA-332
A. hydrophilia (MIC 32 µg/mL)
E. coli (MIC 32 µg/mL)
M. luteus (MIC 64 µg/mL)
P. aeruginosa (MIC 32 µg/mL)
V. alginolyticus (MIC 32 µg/mL)
V. harveyi (MIC 16 µg/mL)
V. parahaemolyticus (MIC 32 µg/mL)
C. gloeosprioides (MIC 16 µg/mL)
Penicisimpins C (148) Penicillium simplicissimum
MA-332
A. hydrophilia (MIC 16 µg/mL)
E. coli (MIC 8 µg/mL)
M. luteus (MIC 16 µg/mL)
P. aeruginosa (MIC 8 µg/mL)
V. alginolyticus (MIC 16 µg/mL)
V. harveyi (MIC 8 µg/mL)
V. parahaemolyticus (MIC 8 µg/mL)
C. gloeosprioides (MIC 8 µg/mL
Citreoisocoumarin (149) Penicillium vinaceum S. aureus (Zone of inhibition 19 mm at 100 µg/disk)
Nucleosides
Rocheicoside A (150) Streptomyces rochei 06CM016
E. coli O157:H7 (MIC 16 µg/mL)
MRSA DSM (MIC 8 µg/mL)
C. albicans DSM (MIC 4 µg/mL)
Plicacetin (151) Streptomyces rochei 06CM016
E. coli O157:H7 (MIC 8 µg/mL)
MRSA DSM (MIC 4 µg/mL)
C. albicans DSM (MIC 8 µg/mL)
Norplicacetin (152) Streptomyces rochei 06CM016
E. coli O157:H7 (MIC 16 µg/mL)
MRSA DSM (MIC 8 µg/mL)
C. albicans DSM (MIC 4 µg/mL)
p-amino benzamido uracil (153) Streptomyces rochei 06CM016
E. coli O157:H7 (MIC 16 µg/mL)
MRSA DSM (MIC 16 µg/mL)
C. albicans DSM (MIC 8 µg/mL)
Cytosamine (154) Streptomyces rochei 06CM016
E. coli O157:H7 (MIC 16 µg/mL)
MRSA DSM (MIC 16 µg/mL)
C. albicans DSM (MIC 8 µg/mL)
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Miscellaneous Compounds
Terretrione A (151) Penicillium vinaceum C. albicans (Zone of inhibition 27 mm at 100 µg/disk)
Terretrione C (152) Penicillium sp. CYE-87 C. albicans (MIC 32 µg/mL)
Terretrione D (153) Penicillium sp. CYE-87 C. albicans (MIC 32 µg/mL)
α-Cyclopiazonic acid (154) Penicillium vinaceum E. coli (Zone of inhibition 20 mm at 100 µg/disk)
5-methoxydihydrosterigmato-cystin
(155)
Aspergillus versicolor S. aureus (MIC 13 µg/mL)
B. subtilis (MIC 3 µg/mL)
Caerulomycin A (156) Actinoalloateichus cyanogriseus
C. albicans (MIC 0.8–1.6 µg/mL)
C. albicans CO9 (MIC 0.8–1.6 µg/mL)
C. glabrata HO5FlucR (MIC 0.4–0.8 µg/mL)
C. krusei GO3FlucR (MIC 0.8–1.6 µg/mL)
Trichodin A (157) Trichoderma sp.
B. subtilis (IC50 27 µM)
S. epidermidis (IC50 24 µM)
C. albicans (IC50 25 µM)
Pyridoxatin (158) Trichoderma sp.
B. subtilis (IC50 4 µM)
S. epidermidis (IC50 4 µM)
S aureus (MRSA), (IC50 4 µM)
C. albicans (IC50 26 µM)
T. rubrum (IC50 4 µM)
1-(10-Aminodecyl) Pyridinium
(159)
Amycolatopsis alba
B. subtilis NCIM 2439 (MIC > 70 µg/mL)
B. pumilus NCIM 2327 (MIC > 90 µg/mL)
S. aureus NCIM 5021 (MIC > 160 µg/mL)
A. formicans NCIM 2319 (MIC > 150 µg/mL)
E. coli NCIM 2067 (MIC > 90 µg/mL)
Porric acid D (160) Alternaria sp. S. aureus (MIC 100 µg/mL)
Altenusin (161) Alternaria sp. S. aureus (MIC 25 µg/mL)
p-Hydroxybenzoic acid (162) Pseudoalteromonas flavipulchra V. anguillarum (MIC 1.25 mg/mL)
trans-Cinnamic acid (163) Pseudoalteromonas flavipulchra V. anguillarum (MIC 1.25 mg/mL)
N-hydroxybenzoisoxazolone (164) Pseudoalteromonas flavipulchra V. anguillarum (MIC 0.25 mg/mL)
Bacilosarcin B (165) Bacillus subtilis S. aureus (MIC 4 µM)
amicoumacin A (167) Bacillus subtilis
S. aureus (MIC 19 µM)
B. subtillis (MIC 19 µM)
Microluside A (169) Micrococcus sp. EG45 E. faecalis JH212 (MIC 10 µM)S. aureus NCTC 8325 (MIC 13 µM)
4. Alkaloids
Alkaloids constitute the largest number of antimicrobial compounds reported from marine species
(Figure 2). Polyoxygenated dihydropyrano[2,3-c]pyrrole-4,5-dione derivatives, pyranonigrin A (16)
and F (17) were isolated and identified from Penicillium brocae MA-231, which is an endophytic fungus
obtained from the fresh tissue of the marine mangrove plant Avicennia marina. These compounds
possess a wide array of antimicrobial activities against a human-, aqua-, and plant-pathogens [34].
Indole diketopiperazine compounds (18–21) identified from the culture extract of Eurotium cristatum
EN-220 (endophytic fungus species obtained from the marine alga Sargassum thunbergii) possess
antimicrobial activities. While rubrumazine B (18) exhibited moderate activity (MIC 64 µg/mL)
against the plant-pathogenic fungus Magnaporthe grisea, echinulin (19), dehydroechinulin (20) and
variecolorin H (21) showed mild activity (MIC 256 µg/mL) against the human pathogen S. aureus. This
particular trend in antimicrobial activity led to an assumption that indole diketopiperazine alkaloids
formed by condensation of a tryptophan residue with a second amino acid such as L-alanine might
have low relevance to the observed antimicrobial activity [35]. In a separate study by Du et al., a set of
indole alkaloids including echinulin (19), cristatumin A (22), cristatumin D (23) and tardioxopiperazine
A (24) were found to be active against Escherichia coli and S. aureus bacteria but were unable to inhibit
the growth of the plant-pathogenic fungi, Alternaria brassicae, Valsa mali, Physalospora obtuse, Alternaria
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solania, and Sclerotinia miyabeana. The antibacterial activity of cristatumin A (22) appeared to be
related to the serine residue in the 2,5-diketopiperazine moiety compared to that of neoechinulin A
(25), which contained an alanine residue. The structural difference between isoechinulin A (26) and
tardioxopiperazine A (24) was found at the C-8/C-9 position, where the single bond between C-8/C-9
in compound 24 was essential for its antibacterial activity [36].
N-alkylated hydantoin alkaloids, such as hemimycalins A (27) and B (28) and
(Z)-5-(4-hydroxybenzylidene)imidazolidine-2,4-dione (29), isolated from the Red Sea sponge,
Hemimycale arabica have previously demonstrated antimicrobial activity against E. coli and C albicans
but were found to be inactive against S. aureus [37]. Peniciadametizine A (30), a dithiodiketopiperazine
derivative possessing a unique spiro [furan-2,7′-pyrazino[1,2-b][1,2]oxazine] skeleton, and its highly
oxygenated analogue, peniciadametizine B (31) were isolated from Penicillium adametzioides AS-53,
a fungus obtained from an unidentified marine sponge collected in Wenchang, Hainan, China.
These compounds exhibited selective activities against A. brassicae but were inactive against bacteria
(Aeromonas hydrophilia, Edwardsiella tarda, E. coli, S. aureus, Vibrio alginolyticus, V. anguillarum, V.
parahaemolyticus, and V. harveyi), and plant-pathogenic fungi (Colletotrichum gloeosporioides, Fusarium
graminearum, and Gaeumannomyces graminis) [38]. The antimicrobial sulfide diketopiperazine
derivatives, penicibrocazines A–E (32–36), were isolated from a culture extract of Penicillium brocae
MA-231, an endophytic fungus obtained from the fresh tissue of the marine mangrove plant Avicennia
marina. Penicibrocazines B–E (compounds 33–36 shown in Figure 2) have demonstrated a wide
spectrum of activity against several human, aquatic and plant-pathogenic microbes including S.
aureus, Micrococcus luteus and Gaeumannomyces graminis but were inactive against Eromonas hydrophilia,
E. coli, V. harveyi, V. parahaemolyticus and the plant-pathogenic fungi, A. brassicae, Colletotrichum
gloeosporioides and Fusarium graminearum. Penicibrocazine A (32) was inactive against this entire
array of microorganisms. The double bonds at C-6 and C-6′ increase the activity against S. aureus
(34 vs. 32). In addition, a higher number of S-methyl groups is likely to strengthen their activity
against G. graminis (35 vs. 32), while keto groups at C-5/5′ (36 vs. 34) are responsible for the enhanced
antimicrobial activity [39]. Crambescidin 800 (37), a pentacyclic guanidine alkaloid isolated from the
sponge Clathria cervicornis, has expressed specific inhibitory activity against Acinetobacter baumannii,
Klebsiella pneumonia and P. aeruginosa [40].
Xinghaiamine A (38), an alkaloid isolated from the marine-derived actinomycete Streptomyces
xinghaiensis NRRL B24674, has exhibited a broad-spectrum of antibacterial activities against both
Gram-negative (Acinetobacter baumannii, P. aeruginosa and E. coli) and Gram-positive pathogens
(S. aureus and B. subtilis). The inhibition of these pathogenic bacteria and clinical MRSA isolates
demonstrates the potential of compound 38 to be an effective antibiotic against multi-drug resistant
pathogens, particularly S. aureus and A. baumanii. However, the molecule displayed no obvious
antifungal activity against C. albicans when tested at concentrations up to 176.64 µM. The sulfoxide
moiety present in Xinghaiamine A (38) is unusual among the metabolites produced by marine
actinomycetes and confers compounds with a broad spectrum of biological activities, including
potent antimicrobial activities [41]. Bioassay-directed fractionation performed on the ethyl acetate
fraction of an organic extract from the Red Sea sponge Hyrtios species yielded the alkaloid compounds,
hyrtioerectines D–F (39–41), which possessed antimicrobial activities against C. albicans, S. aureus and
P. aeruginosa but not against E. coli. The relatively higher antimicrobial activity exerted by compounds
39 and 41 with respect to compound 40 could be attributed to the presence of diphenolic moieties in
their structure. Amidation of the carboxylic moiety in compound 41 exerted a slight effect on activity
when compared to compound 39 [42]. The diterpene alkaloids, ageloxime B (42) and (−)-ageloxime
D (43), were isolated from the marine sponge Agelas mauritiana, isolated from Yongxing island in
the South China Sea. Both compounds (42 and 43) were able to inhibit the growth of C. neoformans.
Compound 42 also exhibited antibacterial activity against S. aureus and MRSA [43]. A manzamine
alkaloid, i.e., zamamidine D (44), was isolated from an Okinawan Amphimedon sp. marine sponge.
Compound 44 is the first manzamine alkaloid possessing a 2,2′-methylenebistryptamine unit as its
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aromatic moiety instead of a β-carboline unit, which affected growth of both bacteria and fungi [44].
Chemical investigation of the marine-sponge derived fungus Penicillium adametzioides AS-53 yielded
the bisthiodiketopiperazine derivatives, adametizines A (45) and B (46), differing in the presence of a
chlorine group at C-7 in compound 45 and hydroxyl in compound 46. The presence of a chlorine atom
at C-7 conferred compound 45 with better antibacterial activity than compound 46 [45].Mar. Drugs 2017, 15, 272 13 of 40 
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Diterpene alkaloids from the sponge Agelas nakamurai collected from the Xisha Islands in the
South China Sea have demonstrated significant antimicrobial potential in vitro against S. aureus, E. coli,
Proteusbacillus vulgaris and C. albicans. Iso-agelasidine B (47) and (−)-agelasidine C (48) exhibited
pronounced antifungal activities (MIC 2.34 µg/mL) against C. albicans and weakly inhibited bacterial
growth. In addition, diterpene alkaloids containing a 9-N-methyladeninium unit: iso-agelasine C (49),
agelasine B (50), agelasine J (51) and nemoechine G (52) also possessed strong antifungal activities
(MIC 0.6 µg/mL) against C. albicans and weak to moderate antibacterial activities [46]. Brevianamide F
(53) was isolated from the marine-derived fungus, Penicillium vinaceum. This compound demonstrated
antimicrobial activity against S. aureus and antifungal activity towards C. albicans [47]. A new secondary
metabolite N-(2-hydroxyphenyl)-2-phenazinamine (54) was isolated from the saline culture broth of
Nocardia dassonvillei, a marine actinomycete recovered from a sediment in the Arctic Ocean. This new
compound has shown significant antifungal activity against C. albicans, with a MIC 64 µg/mL [48].
5. Terpenoids
As many as 26 different types of terpenoids have been found in marine species (Figure 3).
A potent antimicrobial meroterpenoid, puupehenol (55) was isolated from the organic extract of
a deep-water Hawaiian sponge Dactylospongia sp., along with puupehenone (56) which has been
suggested to be a derivative of puupehenol. These compounds exhibited antibacterial activity
towards the Gram-positive bacteria, S. aureus and B. cereus, but no inhibition was observed against
E. coli and P. aeruginosa [49]. The sesquiterpenes, Penicibilaenes A (57) and B (58) isolated from
Penicillium bilaiae MA-267, a fungus obtained from the rhizospheric soil of the mangrove plant
Lumnitzera racemose possess a tricyclo[6.3.1.01,5]dodecane skeleton, which confers antimicrobial
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activities to these compounds. Both of these molecules have demonstrated selective activity against
C. gloeosporioides. Compound 57 proved more active than 58 suggesting that the acetylation of
4-OH enhances the bioactivity of the compound [50]. Sesquiterpenoids including aspergillusene
A (59), (Z)-5-(Hydroxymenthyl)-2-(6′)-methylhept-2′-en-2′-yl)-phenol (60) and sydonic acid (61)
isolated from the sponge-associated fungus, Aspergillus sydowii ZSDS1-F6 displayed antimicrobial
activities against Klebsiella pneumonia and Aeromonas hydrophila [51]. Laurene-type sesquiterpenes,
12-hydroxy isolaurene (62), 8,11-dihydro-12-hydroxy isolaurene (63) and isolauraldehyde (64)
were isolated from the organic extract of the red alga Laurencia obtuse collected off the coast of
Jeddah in Saudia Arabia. These compounds exhibited potent activity against the Gram-positive
bacteria, B. subtilis and S. aureus, with compound 64 proving to be the most active (MIC 35 and
27 µg/mL, respectively). Compound 64 also significantly inhibited C. albicans (MIC of 70 µg/mL)
while, no significant activity against the Gram-negative bacterium P. aeruginosa was observed [52].
Napyradiomycins including Napyradiomycin 1 (65) and 2 (66), Napyradiomycin B2–B4 (67–69)
isolated from marine-derived, Streptomyces strains were found to be active against MRSA [53].
Antibacterial N-N-coupled indolo-sesquiterpene atropo-diastereomers, dixiamycin A (70), dixiamycin
B (71), oxiamycin (72), chloroxiamycin (73) and xiamycin A (74) were isolated from a marine-derived
actinomycete, Streptomyces sp. SCSIO 02999. Compounds 70 and 71 were identified as the first
examples of naturally occurring atropo-diastereomers containing an unusual N-N-coupled dimeric
indolo-sesquiterpene skeleton and a stereogenic N-N axis, whilst compound 72 was characterized to
contain an unusual seven-membered oxa-ring. Interestingly, the two dimeric compounds 70 and 71
displayed better antibacterial activities than the monomers (compounds 72–74) against four tested
strains [54]. Antimicrobial compounds with rare pyrane-based cembranoid structure, sarcotrocheliol
acetate (75) and sarcotrocheliol (76), along with cembranoid, cembrene-C (77), sarcophine (78), and
the aromadendrene sesquiterpenoid, palustrol (79) were isolated from the soft coral Sarcophyton
trocheliophorum. Compounds 75 and 76 displayed significant antibacterial activity, especially against
S. aureus, Acinetobacter sp., and MRSA with MICs ranging from 1.53 to 4.34 µM, while compound 77
demonstrated antifungal activity against Aspergillus flavus and C. albicans with an MIC of 0.68 µM [55].
A sesquiterpenoid quinone, epi-ilimaquinone (80), isolated from the Fijian marine sponge Hippospongia
sp. was found to possess antibacterial activity against MRSA, wild-type S. aureus and VREF and
displayed antifungal activity against amphotericin-resistant C. albicans [56].
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In the past 5 years alone, 15 lipids possessing antibacterial activities were isolated from marine
species (Figure 4). Two cerebrosides, penicillosides A (81) and B (82), were isolated from Red
Sea marine- erived fungi and the fungus Penicillium species isolated from the tunicate Didemnum
species. P nicilloside A (compound 81) displayed antifungal activity towards C. albicans displaying
an inhibition zone of 23 mm, while Penicilloside A (82) possessed ant bacterial activities against
S. aureus and E. coli displayi g inhibition zones of 19 and 20 mm respectively, at 100 µg/disk
concentration [57]. Glyc lipopeptides-ieodoglucomides A–C (83–85), nd a monoacyldiglyc syl
glycerolipid-iedoglycolipid (86) isolated from the fermentation broth of the marine sedim nt-derived
bacterium Bacillus licheniformis displayed promising antimicrobial activities against Gram-positive and
Gram-negative bacteria. Moreover these two pencillosides were also active against the plant pathogenic
fungi Aspergillus niger, Rhizoctonia solani, Colletotrichum acutatum, B. cenerea and C. albicans [58,59].
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Gageotetrins A–C (87–89), fall under a unique class of linear lipopeptides (di- and tetrapeptides)
isolated from a marine-derived Bacillus were found to be comparatively more active against fungi
than to bacteria with MIC values of 0.02–0.04 µM. Moreover, compounds 88 and 89 at a concentration
of 0.02 µM displayed potent motility inhibition and lytic activity against the late blight pathogen
Phytophthora capsici, which causes enormous economic damage in cucumber, pepper, tomato and
beans [60]. Lauramide diethanolamine (90) was isolated from the marine bacterial strain Streptomyces
sp. (strain 06CH80). Although this compound (90) showed moderate antimicrobial activities against
clinical pathogens, its chemical structure is particularly unusual containing a unique carbon skeleton
which is different from any other existing antimicrobial agents. This unusual structure provides
researchers with the exciting opportunity of exploring various chemical modifications of the compound
with the aim of developing of potentially more efficient antimicrobial agents [61]. The unsaturated
fatty acids, linieodolides A (91) and B (92), were isolated from the culture broth of a marine Bacillus
and the mechanism of their antimicrobial activity was proposed through the inhibition of bacterial
fatty acid synthesis [62]. Two highly acetylated steroids, dysiroid A (93) and dysiroid B (94), were
isolated from the marine sponge, Dysidea sp. Compounds 93 and 94 showed potent activity against
bacterial strains with MICs ranging from 4 to 8 µg/mL [63]. Halistanol sulfate A (95) was obtained
from the sponge Petromica ciocalyptoides and determined to be an effective antibacterial compound
against Streptococcus mutans. The compound inhibited S. mutans biofilm formation by down regulating
the expression of the gtfB, gtfC and gbpB virulence genes. Compound 95 inhibited biofilm formation in
two S. mutans strains at low MIC, but did not inhibit initial colonization by S. sanguinis. Such activity
is highly desirable in preventative treatments that inhibits pathogenic bacteria via the disruption of
biofilm formation without affecting the healthy normal microflora [64].
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7. Peptides
Marine derived antimicrobial compounds of peptide origin are shown in Figure 5. Modified
diketopiperazines, rodriguesines A and B (96 and 96a) isolated as an inseparable mixture from
the ascidian Didemnum sp. were found to possess broad antimicrobial activities inhibiting both
oral streptococci and pathogenic bacteria. These diketopiperazines are reported to modulate the
LuxR-mediated quorum-sensing systems of Gram-negative and Gram-positive bacteria and are
considered to influence cell-cell bacterial signaling, offering alternative ways to control biofilms
by interfering with microbial communication [64]. Diketopiperazines, cyclo-(L-valyl-D-proline) (97)
cyclo-(L-phenylalanyl-D-proline (98), were isolated from a Rheinheimera japonica strain KMM 9513
collected from shores off of the Sea of Japan. These diketopiperazines inhibited the growth of B. subtilis,
Enterococcus faecium and S. aureus but were inactive against E. coli, S. epidermidis, Xanthomonas sp. pv.
badrii and C. albicans [65]. Compounds cyclo-(S-Proline-R-Leucine) (99) and (97) were isolated from
Bacillus megaterium LC derived from the marine sponge Haliclona oculata. These compounds showed
antimicrobial activity at MIC values ranging from 0.005 to 5 µg/mL against Gram-negative bacteria V.
vulnificus and V. parahaemolyticus, together with the Gram-positive bacteria B. cereus and M. luteus [66].
Cyclohexadepsipeptides of the isaridin class including isaridin G (100), desmethylisaridin G (101),
desmethylisaridin C1 (102) and isaridin E (103), were identified in the marine bryozoan-derived fungus
Beauveria felina EN-135. These compounds possessed inhibitory activities against E. coli with MICs
in the range of 8–64 µg/mL [67]. Desotamide (104) and desotamide B (105) are cyclic hexapeptides
isolated from the marine microbe Streptomyces scopuliridis SCSIO ZJ46. When these compounds were
explored for their antibacterial potential, notable antibacterial activities against strains of S. pnuemoniae,
S. aureus, and methicillin-resistant Staphylococcus epidermidis (MRSE) were observed [68].
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8. Halogenated Compounds
The chemical structures of halogenated compounds with antimicrobial properties isolated
between 2012 and 2017 are presented in Figure 6. Compounds demonstrating a broad spectrum
of antibacterial activities were polybrominated diphenyl ethers, 2-(2′,4′-dibromophenoxy)-3,5-
dibromophenol (106) and 2-(2′,4′-dibromophenoxy)-3,4,5-tribromophenol (107) isolated from the
marine sponge Dysidea granulosa; and 2-(2′,4′-dibromophenoxy)-4,6-dibromophenol (108) from
Dysidea spp. These brominated ethers exhibited in vitro antibacterial activity against MRSA,
methicillin-sensitive Staphylococcus aureus (MSSA), E. coli O157:H7, and Salmonella. Structurally
compound 106 differed from compound 108 at a bromo-substituted position, and from compound 107
by containing an additional bromo group at the C-4 position. From the structure-activity relationships
it was suggested that bromination and para-substitution decreases the antimicrobial activities of
bromophenols, except against the human pathogen, Listeria monocytogenes [69]. Bromotyrosine-derived
alkaloids were isolated by bioassay-guided fractionation of extracts from the Australian marine sponge
Pseudoceratina purpurea. Aplysamine 8 (109) was not found to have any notable activity against E. coli
or S. aureus while hexadellin (110), aplysamine 2 (111) and 16-debromoaplysamine 4 (112) displayed
activity against S. aureus at concentrations ranging from 125–250 µg/mL [70]. The brominated
diterpene, sphaerodactylomelol (113) which belongs to the rare dactylomelane family, bromosphaerol
(114) and 12R-hydroxybromosphaerol (115) were isolated from cosmopolitan red algae, Sphaerococcus
coronopifolius, collected in the Atlantic. These compounds inhibited the growth of S. aureus but were
inactive against E. coli and P. aeruginosa [71]. A brominated compound, 6-bromoindolyl-3-acetic
acid (116) displayed varied activities against both Gram-positive and Gram-negative bacteria:
V. harveyi, Photobacterium damselae subsp. damselae. A. hydrophila, S. aureus and B. subtilis [72].
The bromopyrrole alkaloids, nagelamides X–Z (117–119), isolated from a marine sponge Agelas sp.
exhibited antimicrobial activity against a range of bacteria and fungi. Compounds 117 and 118
are dimeric bromopyrrole alkaloids with a novel tricyclic skeleton, which consists of spiro-bonded
tetrahydrobenzaminoimidazole and aminoimidazolidine moieties, while compound 118 is the first
dimeric bromopyrrole alkaloid involving the C-8 position in dimerization [73]. The antibacterial
bromotyrosine-derived metabolites, ianthelliformisamines A–C (120–122), were isolated from the
marine sponge Suberea ianthelliformis. Compound 120 displayed selective inhibitory activity against
P. aeruginosa while compound 121 showed little inhibition. The spermine moiety associated with
compounds 120 and 122 appeared to be important for activity against P. aeruginosa, since replacement of
spermine by spermidine in compound 121 reduced the activity significantly. Furthermore, the addition
of an extra cinnamyl derivative in compound 122 to the terminal amine of the spermine chain decreased
the antibacterial selectivity between P. aeruginosa and S. aureus; however the observed selectivity may
be due to differential cell permeability between the Gram-negative and the Gram-positive bacteria [74].
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Antimicrobial marine natural products of polyketide origin are presented in Figure 7. Chemical
investigations of cultures of the marine Streptomyces sp. 182SMLY led to the discovery of the
antimicrobial polycyclic anthraquinone, N-acetyl-N-demethylmayamycin (123), which inhibited the
growth of MRSA with a MIC 20 µM but displayed no inhibition against E. coli [75]. An unusual
antibiotic polyketide with a new carbon skeleton, lindgomycin (124), and ascosetin (125) extracted
from mycelia and culture broth of different Lindgomycetaceae strainswere two folds less active against
the clinically relevant bacteria Staphylococcus epidermidis, S. aureus, MRSA, and Propionibacterium
acnes than standard drug chloramphenicol. The antifungal activity of compound 124 and 125
was four times lower than nystatin against the human pathogenic yeast C. albicans. Moreover
Xanthomonas campestris and Septoria tritici, were also inhibited by these metabolites but no inhibitory
effects against Gram-negative bacteria was observed [76]. Among the polyketide endoperoxides,
manadodioxans D (126) and E (127) isolated from the marine sponge Plakortis bergquistae in
Indonesia, only manadodioxan E (127) displayed antimicrobial activities against bacteria, namely
E. coli and B. cereus. The presence of a carbonyl group at C-13 position in compound 126
possibly has sequestered the antimicrobial activity. However, both compounds were found to be
inactive against C. albicans, and S. cerevisiae [77]. Using antibacterial bioassay-guided fractionation,
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two O-heterocyclic compounds belonging to pyranyl benzoate analogues of polyketide origin
2-(7-(2-Ethylbutyl)-2,3,4,4a,6,7-hexahydro-2-oxopyrano-[3,2b]-pyran-3-yl)-ethyl benzoate (128) and
2-(4Z)-2-ethyl-octahydro-6-oxo-3-(E)-pent-3-enylidene-pyrano-[3,2b]-pyran-7-yl-ethyl benzoate (129),
were isolated from the ethyl acetate extract of B. subtilis MTCC 10407. Two additional homologs,
i.e., (3-(methoxycarbonyl)-4-(5-(2-ethylbutyl)-5,6-dihydro-3-methyl-2H-pyran-2-yl)-butylbenzoate)
(130) and [2-(8-butyl-3-ethyl-3,4,4a,5,6,8a-hexahydro-2H-chromen-6-yl)-ethylbenzoate] (131), were
also isolated from the ethyl acetate extract from the host seaweed Sargassum myriocystum. Although
compounds 130 and 131 displayed weaker antibacterial activities than compounds 128 and 129
these four compounds possessed similar structures suggesting the ecological and metabolic
symbiosis between seaweeds and bacteria. It was evident from the study that the presence of
dihydro-methyl-2H-pyran-2-yl propanoate system was essential to impart the antibacterial activity.
Tetrahydropyran-2-one moiety of the tetrahydropyrano-[3,2b]-pyran-2(3H)-one system of compound
128 might be cleaved by the metabolic pool of seaweeds to afford biologically active methyl
3-(dihydro-3-methyl-2H-pyranyl)-propanoate moiety of compound 130 (which was shown to have no
significant antibacterial activity in intact form) [78].
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Fradimycins A (132) and B (133) isolated from marine Streptomyces fradiae strain PTZ0025
displayed antimicrobial activity against S. aureus [79]. Macrolactins, polyene cyclic macrolactones
possess a wide range of biological activities including antimicrobial, antiviral and anticancer.
The majority of macrolactins are produced by Bacillus sp., whilst glycosylated macrolactins A1 (134)
and B1 (135) are frequently isolated from marine Streptomyces species. The position of the hydroxyl
group (OH) or the introduction of a keto group (C=O) in the macrolactone ring affects the antimicrobial
activity of macrolactins, while the introduction of ester groups at the C-7 in macrolactins leads
to better antibacterial activity. Compounds 134 and 135 were less active than their corresponding
ether-containing macrolactins, probably due to the attachment of a sugar moiety at C-7 position of
both compounds. However, glycosylated macrolactins are reported to have better polar solubility in
comparison to the non-glycosylated macrolactins [61]. From the culture broth of a marine Bacillus
sp., compounds including macrolactones (Macrolactin X–Z, 136–138) and macrolactinic acid (139)
were isolated. These metabolites displayed potential antimicrobial activity against microbial strains,
B. subtilis (KCTC 1021), E. coli (KCTC 1923), and S. cerevisiae (KCTC 7913). Macrolactins exhibit their
antibacterial activity by inhibiting peptide deformylase in a dose-dependent manner. The position of
hydroxy groups in the macrolactone ring is also important for antimicrobial activity of macrolactins.
The hydroxy group at C-15 in macrolactone ring increases the antimicrobial activity of macrolactins,
whereas introduction of carbonyl group at C-15 decreases antimicrobial activity. The number of
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ring members and the presence of a hydroxy group at C-7 and C-9 position have no effect on the
antibacterial activity [62].
Chemical analysis of a marine-derived Streptomyces sp. (CMB-M0392) isolated from sediment
collected off Heron Island, Queensland, Australia, yielded the benzothiazine ansamycins, heronamycin
A (140) and herbimycin A (141). Compound 140 showed antimicrobial activity against B. subtilis ATCC
6051 and 6633, but no activity against S. aureus ATCC 25923 and 9144, E. coli ATCC 11775, P. aeruginosa
ATCC 10145 or C. albicans ATCC 90028 while compound 141 showed antimicrobial activity against
B. subtilis ATCC 6051 and 6633 and C. albicans ATCC 90028 [80]. Antibacterial polyketide compounds
were isolated from the heterotrophic bacterium, Bacillus amyloliquefaciens which is associated with
the edible red seaweed Laurenciae papillosa. Bioactivity-guided techniques resulted in the isolation
of 3-(octahydro-9-isopropyl-2H-benzo[h]chromen-4-yl)-2-methylpropyl benzoate (142) and methyl
8-(2-(benzoyloxy)-ethyl)-hexahydro-4-(E)-pent-2-enyl)-2H-chromene-6-carboxylate (143), compounds
of polyketide origin which demonstrated activity against human opportunistic food pathogenic
microbes. Compounds 142 and 143 demonstrated significant antibacterial activity (inhibitory zone
diameter of greater than 18 mm against V. vulnificus, 25 µg on disk) against these pathogenic
bacteria and lesser activity against A. hydrophilla (14–16 mm, 25 µg on disk) and V. parahemolyticus
ATCC17802TM (inhibitory zone diameter of 12–14 mm, 25 µg on disk). In general antibacterial
activities of compound 142 were greater than 143. Various molecular descriptor variables, such as
bulk, polarizability (electronic), and lipophilicity (octanol/water partition coefficient) were found
to significantly influence the antibacterial activities of these compounds. Although there was no
significant dissimilarities in polarizability of compounds 142 and 143, the activity of the latter was
lesser (inhibition zone diameter, 16 mm against V. vulnificus; 25 µg on disk) than that of the former
(18 mm against V. vulnificus; 25 µg on disk) due to the lesser lipophilicity associated with 143 compared
to 142. The higher lipophilicity of compound 142 enabled the compound to effectively penetrate the
intermembrane lipoprotein barrier to enter the receptor location, resulting in greater bioactivity against
food pathogenic bacteria [81]. 3-O-(α-D-ribofuranosyl)questin (144) and eurorubrin (145) isolated from
the fungal strain Eurotium cristatum EN-220, an endophyte obtained from the marine alga Sargassum
thunbergii displayed antimicrobial activity against E. coli but did not inhibit the growth of S. aureus,
Physalospora obtuse, A. brassicae, Valsa mali, A. solania, and Sclerotinia miyabeana [82].
10. Isocoumarins
Antimicrobial dihydroisocoumarin derivatives penicisimpins A–C (146–148) were reported from
a rhizosphere-derived fungus, Penicillium simplicissimum MA-332 obtained from a marine mangrove
plant Bruguiera sexangula var. rhynchopetala (Figure 8). These isocoumarins possess a broad-spectrum
of antibacterial and antifungal activities. Among these three isocoumarins, penicisimpins A (146)
exhibited the greatest activity against E. coli, P. aeruginosa, V. parahaemolyticus, V. harveyi, and
C. gloeosprioides (each with MIC value of 4 µg/mL) while the other two congeners (147 and 148)
were only moderately active against these pathogens. It was determined that the methyl group
attached at C-7 was responsible for the enhanced activity observed in compound 146 relative to 147,
while the double bond at C-11 was responsible for the decreased activity (compound 146 vs. 148) [83].
The marine-derived fungal species Penicillium vinaceum has been reported to produce citreoisocoumarin
(149) that displayed activity against S. aureus (19 mm inhibition zone) [47].
Mar. Drugs 2017, 15, 272 25 of 42
Mar. Drugs 2017, 15, 272 24 of 40 
 
 
Figure 8. Antimicrobial isocoumarins (146–149) and nucleosides (150–154). 
11. Nucleosides 
Rocheicoside A (150), a nucleoside analogue possessing a novel 5-(hydroxymethyl)-5-
methylimidazolidin-4-one substructure, and several other nucleosides such as plicacetin, 
norplicacetin, p-aminobenzanido uracil and cytosamine (151–154, Figure 8) have been isolated from 
the marine-derived actinomycete Streptomyces rochei 06CM016. These nucleosides have been 
described as potent antibiotics against microorganisms, including archaea, bacteria and eukarya. 
Rocheicoside A (150) displayed potential antimicrobial activity with MIC 4–16 μg/mL against a 
number of pathogens including E. coli, MRSA and C. albicans [84]. 
12. Miscellaneous Compounds 
Several compounds which have not been classified under any of the above subheadings are 
discussed in this section and their chemical structures are illustrated in Figure 9. Terretrione A (151), 
terretrione C (152) and terretrione D (153) containing a 1,4-diazepane skeleton were isolated from an 
organic extract of the fungus Penicillium sp. CYE-87 derived from a tunicate-Didemnum sp. collected 
from the Suez Canal in Egypt. These compounds displayed antimicrobial activity against C. albicans 
but were inactive against S. aureus and E. coli [47,85]. Marine-derived fungi, Penicillium vinaceum 
species when investigated for antimicrobial compounds led to discovery of α-cyclopiazonic acid 
(154), which was active only against E. coli with an inhibition zone of 20 mm [47]. 5-
methoxydihydrosterigmatocystin (155), a compound isolated from the marine-derived fungus, 
Aspergillus versicolor MF359, isolated from a marine sponge of Hymeniacidon perleve was active against 
S. aureus and B. subtilis. The compound did not display activity against MRSA and P. aeruginosa as 
the MIC was found to be >100 μg/mL against both the organisms [86]. Caerulomycin A (156), an 
antifungal compound isolated from marine actinomycetes Actinoalloateichus cyanogriseus showed 
potent activity against Candida isolates, C. albicans and C. albicans CO9, and two fluconazole resistant 
strains namely, C. glabrata HO5Fl and C. krusei GO3. The MICs of Caerulomycin A was in the range 
of 0.39–1.26 μg/mL. Furthermore, the MIC values obtained for Caerulomycin A against fluconazole 
resistant C. glabrata were comparable with the MIC values obtained for Amphotericin B [87]. 
Pyridones, trichodin A (157) and pyridoxatin (158), were extracted from both the mycelia and the 
culture broth of the marine fungus, Trichoderma sp. strain MF106 obtained from the Greenland Seas. 
Compounds 157 and 158 possess moderate antibiotic activities against the Gram-positive B. subtilis, 
S. epidermidis, MRSA and yeast, C. albicans but were inactive against Trichophyton rubrum [88]. A 
Figure 8. Antimicrobial isocoumarins (146–149) and nucleosides (150–154).
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Rocheicoside A (150), a nucleoside analogue possessing a novel 5-(hydroxymethyl)-5-
methylimidazolidin-4-one substructure, and several other nucleosides such as plicacetin, norplicacetin,
p-aminobenzanido uracil and cytosamine (151–154, Figure 8) have been isolated from the
marine-derived actinomycete Streptomyces rochei 06CM016. These nucleosides have been described as
potent antibiotics against microorganisms, including archaea, bacteria and eukarya. Rocheicoside A
(150) displayed potential antimicrobial activity with MIC 4–16 µg/mL against a number of pathogens
including E. coli, MRSA and C. albicans [84].
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(151), terretrione C (152) and terretrione D (153) containing a 1,4-diazepane skeleton were isolated
from an organic extract of the fungus Penicillium sp. CYE-87 derived from a tunicate-Didemnum
sp. collected from the Suez Canal in Egypt. These compounds displayed antimicrobial activity
against C. albicans but were inactive against S. aureus and E. coli [47,85]. Marine-derived fungi,
Penicillium vinaceum species when investigated for antimicrobial compounds led to discovery of
α-cyclopiazonic acid (154), which was active only against E. coli with an inhibition zone of 20 mm [47].
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the marine fungus, Trichoderma sp. strain MF106 obtained from the Greenland Seas. Compounds 157
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and 158 possess moderate antibiotic activities against the Gram-positive B. subtilis, S. epidermidis, MRSA
and yeast, C. albicans but were inactive against Trichophyton rubrum [88]. A pyridinium compound,
1-(10-Aminodecyl) Pyridinium (159), isolated from the marine actinomycete, Amycolatopsis alba var.
nov. DVR D4 demonstrated antimicrobial activities against Gram-positive and Gram-negative bacteria
with MICs in the range of 70–160 µg/mL [89]. A dibenzofuran derivative porric acid D (160) and
altenusin (161) were isolated from the methanol extract of the marine derived fungus, Alternaria sp.,
isolated from the Bohai Sea. These compounds were reported to have antibacterial activity against
S. aureus [90]. Several small molecules including p-hydroxybenzoic acid (162), trans-cinnamic acid
(163) and N-hydroxybenzoisoxazolone (164) were isolated from Pseudoalteromonas flavipulchra and
showed antibacterial activity against Vibrio anguillarum. Greater growth inhibition was observed
in V. anguillarum when a mixture of all three compounds was used compared to when each of the
compounds was used individually, suggesting that they may act in a synergistic manner [72]. The
antimicrobial compounds, bacilosarcin B (165) and C (166) and amicoumacin A (167) and B (168),
were isolated from the culture broth of a marine-derived bacterium B. subtilis. The C-12 amide
group of amicoumacin was found to be crucial for antibacterial activity against MRSA based on
structural comparisons of amicoumacin A (167) and amicoumacin B (168). It was observed that
only the compound amicoumacin A (167) with C-12′ amide groups exhibited antibacterial activities
against B. subtilis, S. aureus and L. hongkongensis, which strongly supported the idea that the C-12′
amide group of amicoumcin acts as a pharmacophore in antibacterial activities. This conclusion was
further supported by comparing antibacterial activities between compounds 167/168 and 165/166.
Compound 167 exhibited antibacterial activities against B. subtilis, S. aureus and L. hongkongensis,
which were about six-fold higher than those of 168 [91]. Microluside A [4-(19-p-hydroxybenzoyloxy-
O-β-D-cellobiosyl)-5-(30-p-hydroxybenzoyloxy-O-β-D-glucopyranosyl)xanthone] (169) is a unique
O-glycosylated disubstituted xanthone isolated from the broth culture of Micrococcus sp. EG45 isolated
from the Red Sea sponge Spheciospongia vagabunda. Compound 169 exhibited antibacterial activities
against E. faecalis JH212, and S. aureus NCTC 8325 [92].
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13. Synthetic Interventions
Although naturally occurring marine natural products are bestowed with interesting structural
features (both chemical and stereochemical), some pharmacophoric modifications are still required to
improve their biological efficacy [93]. In this respect, several synthetic chemists are engaged in tailoring
these natural products to obtain new chemical entities by modifying their natural structures [94]
(Figure 10). Recently, Sakata et al. identified isatin (170), an algicidal substance produced by the
marine bacterium Pseudomonas sp. C55a-2 isolated from coastal sea water of Kagoshima Bay in
Japan and targeted this compound for synthetic modification. This particular compound was chosen
as many strains belonging to the genera Pseudomonas, Alteromonas and Pseudoalteromonas sp. have
previously been reported to use chemical defences in the form of extracellular agents like isatin. With
background knowledge of the antifungal activities of isatin, several structural modifications were
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made to the compound including bromination of the C-5 carbon of the isatin ring, altering the length
of its alkyl chain and N-protections, resulting in the development of molecules with potentially better
pharmacophoric features. Structure-activity relationships revealed that a bromine substitution at
the C-5 carbon atom in isatin derivatives led to a decrease in antibacterial activity when compared
structurally to the parent isatin molecule. The antibacterial activity remains unchanged for N-methyl
and N-butyl isatin derivatives, however, the addition of a free NH group to the structure of these
compounds results in a decrease in antibacterial activity. Hence, it can be deduced that the free
NH moiety of isatin is necessary for its potent inhibitory activities against fouling bacteria. The
antibacterial activity was found to be better in the class of compounds wherein acetonyl moiety is
introduced as functionality, compared to more extended hydrophobic benzoyl, as well as electron
donating ethoxy group. Compounds 171–173 from this group exhibited a greater inhibitory effect
compared to the parent compound 170 and to the N-protected isatins 174–179 and the 5-bromoisatin
derivatives 180–182. The presence of a 3-acetonylidene group and a free NH moiety in compounds
171–173 were determined to be crucial structural elements responsible for enhancing the antibacterial
activity of these compounds [95].
Bromopyrrole alkaloids are produced by marine sponges and possess an array of diverse
biological activities, including antimicrobial and antineoplastic activities [96–98]. Many of these
molecules are readily identifiable by a 4,5-dibromopyrrole ring contained within their structure, with
oroidin (183) being the best characterized of these alkaloids noted for its antibiofilm activity [99] In
2012, Rane et al. synthesized marine bromopyrrole alkaloid derivatives containing 1,3,4-oxadiazole
and thiazolidinone and evaluated their antimicrobial and antibiofilm properties. Compounds
184–188 are among these synthetic oroidin derivatives containing 1,3,4-oxadiazole and have exhibited
antimicrobial activity against representative Gram-positive and Gram-negative bacteria [100,101].
These compounds demonstrated antibacterial activity comparable to ciprofloxacin® when used
against S. aureus (MIC = 1.56 µg/mL). Further substitutions of 1-methyl-4,5-dibromopyrrole core
with 4-thiazolidinone had been synthesized and tested for antibiofilm potentials against few
Gram-positive bacteria. 4-thiazolidinone derivatives, compounds 189 and 190 showed antibiofilm
activities (MIC = 0.78 µg/mL) 3-fold superior than those exerted following standard Vancomycin® use
(MIC = 3.125 µg/mL), while activity of compounds 191–194 was 2-fold (MIC = 1.56 µg/mL) higher
against S. aureus biofilm formation. Compounds 189–195 showed equal antibiofilm activity against
S. epidermidis compared to standard Vancomycin (MIC = 3.125 µg/mL) [102].
In 2014, Zidar et al. isolated marine alkaloids, clathrodin (196) and oroidin (183), from sponges of
the genus, Agelas, which possess significant antimicrobial activity against the bacterial strains E. faecalis,
S. aureus and E. coli and C. albicans. The research group synthesized several derivatives using oroidin
as a template. The most bioactive of all these derivatives was found to be 4-phenyl-2-aminoimidazole
(197), which exhibited an MIC90 value of 12.5 µM against Gram-positive bacteria and 50 µM against
E. coli [103].
A new marine-derived monoterpenoid compound, penicimonoterpene (+)-1 (198), was isolated
from Penicillium chrysogenum QEN-24S in 2014 and had shown antifungal activity against A. brassicae
and potent antibacterial activity against marine bacteria Aeromonas hydrophila, V. harveyi, and
V. parahaemolyticus. This activity pattern encouraged chemists to develop a number of derivatives
of compound 198. Modifications focused on variation of the substituents at the C-8 position, the
carbon-carbon double bond at the C-6/7 position, and carboxyl substituents at the C-1 position.
Compounds 199–203 were synthesized according to these modifications and found to be particularly
active against F. graminearum. It was determined that oxidation of the methyl to a hydroxymethyl
group at the C-8 position or replacement of the methyl ester group at C-1 by an ethyl ester significantly
increased the antifungal activity of these compounds. Compounds with a reduced double bond at
C-6/7 also showed better inhibitory activities against gloeosporioides and F. graminearum except for
those containing an aldehyde group [104].
Mar. Drugs 2017, 15, 272 29 of 42
Mar. Drugs 2017, 15, 272 29 of 41 
 
 
Figure 10. Semi-synthetic derivatives of MNPs. 
14. Genome Mining of Marine Microorganisms—The Future of Antimicrobial Discovery 
Antimicrobial compound discovery has traditionally mainly relied on bioassay-guided 
approaches involving the cultivation of microorganisms under a variety of growth conditions, the 
subsequent screening of culture extracts for bioactivity and chemical characterization of the 
compounds produced. Over time however, this approach has led to the frequent re-isolation of 
known compounds, resulting in a drastic decline in research efforts being undertaken by research 
groups and pharmaceutical companies [105], causing a significant deficit in the number of novel, 
Figure 10. Semi-synthetic derivatives of MNPs.
14. Genome Mining of Marine Microorganisms—The Future of Antimicrobial Discovery
Antimicrobial compound discovery has traditionally mainly relied on bioassay-guided
approaches involving the cultivation of microorganisms under a variety of growth conditions,
the subsequent screening of culture extracts for bioactivity and chemical characterization of the
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compounds produced. Over time however, this approach has led to the frequent re-isolation of known
compounds, resulting in a drastic decline in research efforts being undertaken by research groups
and pharmaceutical companies [105], causing a significant deficit in the number of novel, natural
products available for commercial and medicinal use. In this age of antimicrobial resistance, the
demand for functionally diverse, unique antimicrobials has never been greater. Fortunately, advances
in sequencing and ‘-omics’ based technologies have revived the field of natural product discovery in
recent years, owing in large part to the cost effectiveness and speed associated with next-generation
sequencing. With more than 99,000 sequenced bacterial genomes currently publically available in the
NCBI database [106] and sequence data from thousands of metagenome projects which can be accessed
at the Genomes OnLine Database [107], researchers are now focusing their efforts on genome-guided
investigations as a complementary approach to traditional bioactivity-guided methods in an effort to
expedite the identification of ’talented’ microbes, which are likely to possess the biosynthetic machinery
typically associated with antimicrobial compound production.
Biosynthetic gene clusters (BGCs) are specialised groups of genes located in close proximity to
each other in bacterial genomes and encode successive steps in the biosynthesis of natural products.
Sequence-based detection, analysis and functional elucidation of these clusters are paramount to
unlocking the true biosynthetic potential which resides within a microorganism. However functional
elucidation of the products of these BGCs is not always easy, since most are either poorly expressed
or not expressed at all under common laboratory culture conditions. Such was the case observed
for the model antibiotic-producing actinobacterium, Streptomyces coelicolor, which, prior to having its
entire genome sequenced in 2002 [108] was thought to contain BGCs responsible for the production of
six distinct metabolites, previously identified by classic molecular genetic approaches [109]. However,
upon inspection of the organism’s complete genome sequence, 16 additional BGCs including BGCs
potentially encoding nonribosomal peptide synthetases (NRPSs) and polyketide synthases (PKSs) were
identified by bioinformatics-based predictions [110,111]. These clusters were deemed likely to encode
enzymes involved in the synthesis of polyketides and nonribosomal peptides which are considered
to be among the more valuable classes of microbial secondary metabolites from a biopharmaceutical
perspective [112,113].
At the time of writing this review, data pertaining to over one million putative gene clusters
currently resides in the Atlas of Biosynthetic gene Clusters which forms part of the Integrated Microbial
Genomes component of the Joint Genome Institute (JGI IMG-ABC) [114]. With such a wealth of
sequence information available, the challenges researchers now face primarily centre on how to
effectively mine such a huge quantity of data in order to rapidly identify biosynthetically ’talented’
microorganisms and furthermore, how to prioritize which BGCs to investigate among such a vast
collection of uncharacterized clusters when targeting a desired anti-microbial bioactivity.
In this respect the Secondary Metabolite Bioinformatics Portal (SMBP), functions as a useful access
point for investigators; containing website links to databases and tools used in genome mining and
secondary metabolism research [115]. Automated tools such as antiSMASH [116] BAGEL [117] and
PRISM [118] and databases such as Bactibase [119] ClusterMine360 [120] and MIBiG [121] represent
just a few of the sophisticated in silico analytical tools which have quickly established themselves as
the go-to resources for BGC identification, characterization and comparison. antiSMASH (antibiotics
and Secondary Metabolite Analysis Shell) in particular is one of the most extensively used open-source
BGC mining tools. Integrating and cross-linking several analysis tools including BLAST+, HMMer3
and FastTree, this computational platform not only facilitates the detection of known BGCs but can
also detect unknown, BGC-like regions in genomes via ClusterFinder [122] an algorithm which uses
Pfam domain, pattern based predictions to detect putative BGCs. ClusterFinder works on the premise
that even the biosynthetic pathways for unknown compounds are likely to use the same broad families
of enzymes for the catalysis of key reactions. The antiSMASH framework has been continuously
developed [116,123] since its launch in 2010 [124]. antiSMASH version 4.0 was recently released
in April 2017 [125] and contains improvements in prediction software for specialized secondary
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metabolites, including ribosomally synthesized and post-translationally modified peptides (RiPPs)
and terpene products and has been expanded from BGC mining in bacteria and fungi to BGC mining
in plants [126]. Another recently developed tool is EvoMining, which integrates evolutionary concepts
related to the emergence of natural product biosynthesis into genome mining. It is a newly developed
phylogenomics approach toward BGC analysis and has been successfully used in the retrieval of
arseno-organic BGCs, which were previously unobtainable via antiSMASH analysis [127].
With respect to the specific identification of antibacterial compounds and the pathways involved in
their biosynthesis, genome mining approaches have proven useful in the identification of these types of
compounds from marine derived bacteria. Figure 11 highlights a number of antimicrobial compounds
discovered via genome mining approaches. The gene cluster involved in the biosynthesis of
heronamide F (204) was identified following genome scanning of the deep-sea derived Streptomyces sp.
SCSIO 03032. Heronamides are polyketide macrolactams which belong to a class of potent antifungal
metabolites that are produced by marine-derived actinomycetes [128]. Confirmation of the involvement
of this cluster in the biosynthesis of heronamide F was achieved by the functional confirmation of one of
the genes in the cluster, namely herO, encoding a cytochrome P450 by gene knockout experiments [129].
Another example resides with three cyclohexapeptides, destomides B–D (205–207) which were initially
isolated from the marine microbe Streptomyces scopuliridis SCSIO ZJ46. Destomide B was found to
display antibacterial activity against strains of Streptococcus pneumonia, Staphylococcus aureus and
methicillin-resistant Staphylococcus epidermidis (MRSE) [68]. Genome mining identified a putative 39-kb
desotamide dsa gene cluster in the S. scopuliridis strain, and was determined to contain three NRPS
genes. Subsequent heterologous expression of the dsa gene cluster in the heterologous host S. coelicolor
M1152 confirmed its involvement of the biosynthesis of desotamides [130]. Finally, another recent
example involving ribosomally synthesized and post-translationally modified peptides (RiPPs), centres
on the new cinnamycin-like lantiobiotic, mathermycin (208) which has recently been isolated from
the marine-derived strain, Marinactinospora thermotolerans SCSIO 00652 and possesses antimicrobial
activities towards Bacillus subtilis [131]. Genome mining of the strain facilitated the identification
of the BGC for mathermycin, while subsequent expression of the gene cluster in the heterologous
Streptomyces lividans host system allowed its antibacterial activity to be assessed.
Another popular approach in the identification of novel marine derived antimicrobials is to couple
genomics with metabolomics, whereby genome mining together and metabolic profiling are used
to identify novel natural products in marine microorganisms. Our group has previously employed
this approach to identify bioactive compounds from Streptomyces sp. (SM8) isolated from the sponge
Haliclona simulans which displayed antibacterial and antifungal activity [132]. Similarly, Paulus and
co-workers employed both metabolomic and genomic profiling approaches on the marine Streptomyces
sp. MP131-18 to identify a number of new biologically active compounds, including two new members
of the bisindole pyrroles spirorindimycins, spiroindimicin E (209) and F (210). In addition, two new
members of the α-pyrone lagunapyrone family, namely lagunapyrone D and E were also identified
using similar approaches [133]. Another example of the successful use of this coupled approach resides
in marformycins A-F (211–216), which display selective anti-microbial activity against Micrococcus
luteus, Propioniobacterium acnes and Propionobacterium granulosum. The marformycin gene cluster was
identified following genome scanning of the deep-sea sediment-derived Streptomyces drozdowiczii
SCSIO 10141 strain. Confirmation of the involvement of this cluster in the biosynthesis of this
group of cyclic peptides was achieved following in vivo inactivation studies coupled with metabolite
identification [134].
Other techniques have also been developed to expedite the identification of BGCs, which include
mining for the presence of self-resistance mechanisms within these gene clusters, allowing investigators
to deduce the antibiotic compounds which an organism is likely to produce. Resistance mechanisms
are characteristic traits associated with antibiotic producers, enabling an organism to avoid suicide
from self-toxicity following the biosynthesis of its own molecule [135]. Resistance mechanisms include
enzymes which degrade toxic compounds, efflux pumps for the effective removal of unwanted
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substances from the cell and target modification [136]. Wright and colleagues first used resistance
as a discriminating criterion in 2013, demonstrating that organisms resistant to glycopeptide and
ansamycin antibiotics are more likely to produce similar compounds [137]. Following this resistance
based hypothesis increased the discovery rate of producers of the aforementioned antibacterial
compounds by several orders of magnitude. Harnessing the success of this approach, Wright and
colleagues further devised a method for isolating scaffold-specific antibacterial producers by taking
advantage of the innate self-protection mechanisms employed by the producing organisms, isolating
strains in the presence of a selective antibiotic [138]. In 2015, Moore and colleagues developed
a target-directed genome mining method to identify BGCs [139]. As previously mentioned target
modification is one of several resistance strategies employed by antibiotic producing bacteria and
is effective in correlating an antibiotic to its mode of action. Since it is common for antibiotic
producing bacteria to mutate and duplicate genes encoding proteins for resistance, Moore’s group
reasoned that identifying target-duplicated genes which are co-clustered with BGCs would provide
valuable information pertaining to the molecular targets of the BGC products without any prior
knowledge of the molecule synthesized. Since antibiotic targets are often the product of housekeeping
genes, Moore and colleagues screened 86 Salinispora bacterial genomes for duplicated copies of
housekeeping genes and related them to their presence in BGCs. Using this approach they successfully
identified a duplicated fatty acid synthase in the direct vicinity of an orphan hybrid PKS-NPRS
gene cluster and prioritized this for investigation. Following cloning, heterologous expression and
mutational analysis, the authors linked the gene cluster to the biosynthesis of thiolactomycin (217)
a previously characterized fatty acid synthase inhibitor, and to the production of a group of unusual
thiotetronic acid natural products [139]. In 2016, Oakley and colleagues provided experimental
validation for target-directed genome mining in a fungal BGC system [140]. The group identified
a proteasome subunit-encoding gene within a gene cluster in Aspergillus nidulans and hypothesized
that the cluster may be responsible for the production of a proteasome inhibitor. Following a number
of molecular genetic based strategies, the investigators determined that the product of the cluster
was indeed a proteasome inhibitor, fellutamide B (218). Recently, Johnston and co-workers used
resistance-based mining to predict natural products with new modes of action [141]. The authors used
a retrobiosynthetic algorithm to mine biosynthetic scaffolds and resistance determinants to identify
structures with unknown modes of action. Using this approach, the investigators determined that
the telomycin family of natural products from Streptomyces canus possess a new antibacterial mode of
action which targets cardiolipin, a bacterial phospholipid.
Tracanna and co-workers recently suggested another strategy as a means of prioritizing BGCs
which may encode novel antibiotics, based on synergistic interactions [142]. Natural products can occur
as synergistic pairs in nature, as in the case of cephamycin and clavulanic acid, two compounds which
are naturally produced by Streptomyces clavuligerus. The BGCs for these compounds are intertwined
in a ‘supercluster’ configuration [143,144]. This genetic conformation inspired the production of the
antibiotic, Augmentin®, which is comprised of a combination of the β-lactam antibiotic, amoxicillin
with the β-lactamase inhibitor, clavulanic acid. Synergistic pairs of natural products are particularly
attractive commodities in the ongoing attempt to tackle antimicrobial resistance, as it is more difficult
for a pathogen to develop resistance to both compounds. They suggest that thorough analysis
surrounding the evolutionary history of the genes associated with large, hybrid BGCs may provide
a valuable insight into whether these BGCs are in fact ‘superclusters’, responsible for the production of
a number of different compounds which may be synergistic.
It is important that in silico analytical tools keep pace with these genome-guided discovery
strategies in order to expedite novel compound discovery. The Antibiotic Resistant Target Seeker
(ARTS) is one such web tool which uses three criteria to detect known resistance genes as well as
putative resistance house-keeping genes in actinobacterial genomes i.e., (i) duplication (ii) evidence
for horizontal gene transfer (HGT) and (iii) localization within a BGC [145]. This inexpensive,
computational analysis tool, facilitates high-throughput screening of bacterial genomes. Although the
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current focus of ARTS is on the analysis of actinobacterial genomes, the pipeline also works for other
phyla and is being expanded to include reference sets for other taxa. Several other useful resources
are available pertaining to the field of antimicrobial resistance, with the Comprehensive Antibiotic
Resistance Database (CARD) [146] and Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT) being
the two most extensive databases [147].Mar. Drugs 2017, 15, 272 32 of 40 
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15. Concluding Remarks and Future Prospects
The marine environment is home to a vast number of macro and microorganisms with untapped
biosynthetic activities which are used to a large extent to ensure their survival in this diverse and
often hostile habitat. This unique environment facilitates the biosynthesis of an array of secondary
metabolites which act as chemical defenses and display a broad range of antimicrobial bioactivities.
Nevertheless, despite extensive structural and stereo chemical diversity, only seven marine-derived
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metabolites have to date been approved as drugs, while 12 MNPs (or derivatives thereof) are currently
in different phases of clinical trials.
As previously noted, none of the newly discovered marine natural products have as yet progressed
to clinical trials, although a few of them are in preclinical studies. The slower pace of MNPs towards
clinical trials is due to several factors that hinder their development as clinical agents. One of the major
factors is the “continuous supply”. Large quantities of a compound are required to carry out biological
assays to determine the site of action, specific targets, selectivity of the compound and its cytotoxicity.
Irrespective of the potential applications of a functionally promising compound, a significant challenge
faced by researchers is that several hundred grams of the compound are required for preclinical
development, and multi kilogram quantities required for clinical trials. This is often one of the major
bottle-necks in the development of MNP for clinical applications. Synthetic chemists around the world
however are continuing to develop synthetic and semi-synthetic strategies to help overcome the supply
issue surrounding MNPs, in an effort to satisfy the requirements to help bring these molecules to the
preclinical stage and eventual development for use in the commercial or medicinal arenas.
MNPs can be chemically modified with various biosteric structural units to develop ‘drug-like’
molecules. Also, developments in mariculture (farming the growth of the organism in its natural
environment) and aquaculture (culturing an organism under artificial conditions) have been attempted
in order to solve the problem of sustainable supply of macroorganisms. However, the unique and
sometimes exclusive conditions of the sea make cultivation or maintenance of isolated samples still
very challenging and often impossible.
The preclinical pipeline also demands elaborate, mechanistic and pharmacokinetic studies
to develop tailored MNPs, which in itself is a hugely challenging but nevertheless exciting task.
Regardless of these challenges, the preclinical pipeline continues to supply studies with several
hundred novel bioactive marine compounds with the potential for use as therapeutics. From a
global perspective, the marine pharmaceutical pipeline remains very active, and now appears to
have sufficient momentum to deliver additional antimicrobial compounds to the marketplace in the
near future. The efficiency of various marine compounds against pathogens is very encouraging and
there is no doubt that their exploitation and application will continue to develop. Genome mining
has ushered in a renaissance in the field of natural product discovery, providing new hope in the
ongoing search for novel antimicrobial compounds. This strategy allows researchers to harness the
true biosynthetic potential which resides within diverse groups of marine microorganisms and offers
an invaluable insight into not only the biosynthetic, but also the evolutionary and defensive strategies
these organisms employ in the marine environment. Collaborative endeavours involving marine
natural products chemistry with organic chemistry, medicinal chemistry, pharmacology, biology,
bioinformatics and associated disciplines will help to ensure and facilitate an increase in marine
natural product reaching the market as antimicrobial therapeutics.
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